

**BC Cancer Benefit Drug List  
April 2024**

DEFINITIONS						
Class I		Reimbursed for active cancer or approved treatment or approved indication only.				
Restricted Funding (R)		Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application is necessary to provide the appropriate clinical information for each patient.				
NOTES						
1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required.						
2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated.						
3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified.						
4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or cap_bcca@bccancer.bc.ca						
DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
abemaciclib	tablet	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEI	R	
			Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	UBRAJABET	R	
abiraterone	tablet	Genitourinary	Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone	GUMCSPABI	I	
			Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and prednisone	UGUPABI	R	
			Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer using Abiraterone and predniSONE	UGUPAJABI	R	
acalabrutinib	capsule/tablet	Lymphoma	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib	LYACAL	I	
			Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib	LYFACAL	I	
acitretin	capsule	Lymphoma	reversal of early dysplastic and neoplastic stem changes	LYNOS	I	
afatinib	tablet	Lung	first-line treatment of epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer with afatinib	LUAVAFAT	I	
aldesleukin	injectable	Skin & Melanoma	Treatment of In-Transit Melanoma with Intralesional Aldesleukin IL-2	SMLALD	I	
		Pediatric	pediatric patients with high risk neuroblastoma treated on the ANBL0032 study treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in combination with sargramostim, aldesleukin and tretinoin		I	
alectinib	capsule	Lung	treatment of ALK-positive advanced non-small cell lung cancer with alectinib	LUVALE	I	
alemtuzumab	injectable	Lymphoma	treatment of fludarabine-refractory B-chronic lymphocytic leukemia and T-prolymphocytic leukemia	LYALEM	I	
alitretinoin	tablet	Lymphoma	Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides/ Sézary Syndrome)	LYALIT	I	
aminolevulinic acid (LEVULAN® KERASTICK®)	topical solution	Skin & Melanoma	topical therapy for skin cancer with PDT (Photodynamic Therapy)	SMPDT	I	Only reimbursable when prescribed by physicians in the Skin Tumour Group within the BC Cancer Skin PDT Program
amsacrine	injectable	Leukemia & BMT		LKNOS	I	
anagrelide	capsule	Leukemia & BMT	patients with thrombocytosis related to a myeloproliferative disorder who have had an inadequate response to or are intolerant of hydroxyurea and/or interferon	LKANAG	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
anastrozole	tablet	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEI	R	
			neoadjuvant or adjuvant therapy for breast cancer using anastrozole in postmenopausal women	BRAJANAS	I	
			Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer first or second line hormonal treatment for advanced breast cancer in postmenopausal women	BRAJLHRHAI	I	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVANAS	I	
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	BRAVLHRHAI	I	
			therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist	BRAVPALAI	I	
			hormonal treatment for advanced endometrial cancer in postmenopausal women with contraindications to tamoxifen or intolerant of tamoxifen	BRAVRIBAI	I	
		therapy for advanced ovarian cancer using an aromatase inhibitor	GOENDAI	I		
apalutamide	tablet	Genitourinary	Treatment of Metastatic Castration Sensitive Prostate Cancer using Apalutamide	GUMCSPAPA	I	
			Treatment of Non- Metastatic Castration Resistant Prostate Cancer Using Apalutamide	UGUPAPA	R	
arsenic trioxide	injectable	Leukemia & BMT	first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide and tretinoin	LKATOATRA	I	
			first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin	LKATOP	I	
			induction and consolidation therapy of relapsed acute promyelocytic leukemia using arsenic trioxide and tretinoin (All-Trans Retinoic Acid)	LKATOR	I	
		Pediatric	Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and Dexamethasone on the COG AAML1331 Study		I	
asciminib	tablet	Leukemia & BMT	Treatment of Chronic Myeloid Leukemia using Asciminib	LKCLA	I	
asparaginase (KIDROLASE®)	injectable	Leukemia & BMT		LKNOS, LYNOS	I	
asparaginase-erwinia (ERWINASE®)	injectable	Leukemia & BMT	treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma using asparaginase-Erwinia (Erwinase®) in patients allergic to asparaginase (Kidrolase®) or pegaspargase (Oncaspar®)	LKNOS, LYNOS	I	
atezolizumab	injectable	Gastrointestinal	First-Line Treatment of Advanced Hepatocellular Carcinoma using Atezolizumab and Bevacizumab	GIATZB	I	
			Treatment of Resected Non-Small Cell Lung Cancer using Atezolizumab	ULUJATZ	R	
		Lung	Treatment of Advanced Non-Small Cell Lung Cancer Using Atezolizumab	LUAVATZ	I	
			Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Atezolizumab	LUAVATZ4	I	
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide	LUSCATPE	I	
avelumab	injectable	Genitourinary	Maintenance Therapy of Locally Advanced or Metastatic Urothelial Carcinoma using Avelumab	GUBAVE	I	
		Skin & Melanoma	second-line treatment of recurrent or metastatic merkel cell carcinoma using avelumab	SMMCCAVE	I	
axicabtagene ciloleucel (YESCARTA)	CAR T-cell	Lymphoma	Third line treatment of adults with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)	LYCARTDL3	R	
			Third line treatment for adults with primary mediastinal B-cell lymphoma	LYCARTPM3	R	
axitinib	tablet	Genitourinary	therapy for metastatic renal cell carcinoma using axitinib	GUAXIT	I	
			Treatment of Metastatic Renal Cell Carcinoma Using Pembrolizumab and Axitinib	GUAVPEMAX	I	



**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
bevacizumab (cont'd)	injectable	Gynecology	Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine	GOOVBEVV	I	Note: Biosimilar bevacizumab (ZIRABEV®, AYBINTIO®) is funded for treatment started on or after November 1st, 2019. AVASTIN® is funded for treatment started prior to November 1st, 2019.
			primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel	GOOVCATB	I	
		Pediatric	treatment with bevacizumab as a single agent or in combination with chemotherapy for pediatric patients with low-grade glioma progressing after first-line chemotherapy		I	
		Sarcoma	therapy for advanced solitary fibrous tumours and hemangiopericytoma using temozolomide and bevacizumab	SATEMBEV	I	
bexarotene (SAP)	capsule	Lymphoma	patients with refractory cutaneous T-cell lymphoma	LYMFBEX	I	Approval from Health Canada Special Access Programme is required for each patient.
bicalutamide	tablet	Genitourinary	Treatment of Prostate Cancer with High-Dose Bicalutamide	GUPHDBIC	I	Not reimbursed for vasomotor symptoms (hot flashes)
			Non-Steroidal Treatment of Prostate Cancer, at 50 mg po daily	GUPNSAA	I	
binimetinib	tablet	Skin & Melanoma	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Encorafenib and Binimetinib	SMAVEB	I	
bleomycin	injectable	Gynecology	therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide, and cisplatin	GOBEP	I	Not reimbursed for pleurodesis
		Genitourinary	curative therapy for germ cell cancer using with bleomycin, etoposide, cisplatin for germ cell cancers	GUBEP	I	
		Kaposi's Sarcoma	palliative therapy for kaposi's sarcoma using vinblastine alternating with vincristine	KSVB	I	Not reimbursed for pleurodesis
		Lymphoma	treatment of Hodgkin lymphoma with doxorubicin, bleomycin, vinblastine, and dacarbazine	LYABVD	I	
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I	
	Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I		
blinatumomab	injectable	Leukemia & BMT	Treatment of Philadelphia chromosome (Ph)-positive or Ph-negative refractory or relapsed pre-B-cell acute lymphoblastic leukemia with blinatumomab	ULKBLIN	R	
			Treatment of Pre-B-Cell Acute Lymphoblastic Leukemia with Minimal Residual Disease using Blinatumomab	ULKMRDBLIN	R	
		Pediatric	Treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory pre-B-cell acute lymphoblastic leukemia using blinatumomab		R	
			Pediatric patients with Philadelphia chromosome-negative and CD19-positive pre-B-cell acute lymphoblastic leukemia (ALL) in complete hematologic remission (CR) and with minimal residual disease (MRD) positivity		R	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
bortezomib	injectable	Lymphoma	Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	LYDARCBD	I	
		Myeloma	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone	MYBLDF	I	
			Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant	MYBLDPRE	I	
			Maintenance Therapy of Multiple Myeloma using Bortezomib for Patients with the High-Risk Chromosome Abnormality	MYBORMTN	I	
			Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant	MYBOPRE	I	
			Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide	MYBORREL	I	
			Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide	MYBSD	I	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide	MYDARBD	I	
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	MYDARCBD	I	
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR	I	
		Pediatric	Treatment of Children with T-cell Lymphoblastic Lymphoma with Bortezomib		I	
			Bortezomib with chemotherapy for pediatric patients with T-cell lymphoblastic lymphoma treated with on the AALL1231 study		I	
		bosutinib	tablet	Leukemia & BMT	treatment of chronic myeloid leukemia using bosutinib	LKCMLB
brentuximab vedotin	injectable	Lymphoma	Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin	LYAVDBV	I	
			treatment of Hodgkin lymphoma and anaplastic large cell lymphoma with brentuximab vedotin	LYBRENTUX	I	
			treatment for consolidation therapy post-autologous stem cell transplant (ASCT) for Hodgkin lymphoma using brentuximab vedotin	LYBV	I	
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients 60 Years or Older	LYBVAVDBV	I	
			treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin	LYCHPBV	I	
			Treatment of Cutaneous T-Cell Lymphoma (CTCL) with Brentuximab Vedotin	LYCTCLBV	I	
	injectable	Pediatric	pediatric patients following autologous hematopoietic stem cell transplant (HSCT) for relapsed or refractory Hodgkin lymphoma		I	
brexucabtagene autoleucl (TECARTUS)	CAR T-cell	Leukemia & BMT	Treatment of relapsed B-cell acute lymphocytic leukemia (ALL) within 12-months of first remission, refractory/relapsed after two or more treatments, or after an allogeneic stem cell transplantation, OR Ph+ disease with intolerance to tyrosine kinase inhibitors (TKIs) or refractory/relapsed after two or more TKIs	LKCARTALL3	R	
		Lymphoma	Treatment of adults with relapsed or refractory mantle cell lymphoma after 2 or more lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor	LYCARTMC3	R	
brigatinib	tablet	Lung	First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Brigatinib	LUAVBRI	I	
bromocriptine	tablet, capsule	Neuro-Oncology	therapy for pituitary adenomas using bromocriptine	CNB	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
buserelin	long-acting injectable	Breast	Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	BRAJLHRHAI	I	Not reimbursed for endometriosis
			neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen	BRAJLHRHT	I	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVLHRHAI	I	
			combination therapy with tamoxifen as palliative therapy for metastatic breast cancer	BRAVLHRHT	I	
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	BRAVPALAI	I	
			Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	BRAVPBFLV	I	
			Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist	BRAVRBFLV	I	
			therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist	BRAVRIBAI	I	
busulfan	tablet	Not Otherwise Specified	therapy for prostate cancer using LHRH agonist	GUPLHRH	I	Not reimbursed for endometriosis
busulfan	injectable	Leukemia & BMT Pediatric	myeloablative conditioning therapy prior to hematopoietic stem cell transplantation for myeloid malignancies	BMTIVBUCY	I	
			pediatric patients who cannot swallow oral busulfan			
cabazitaxel	injectable	Genitourinary	palliative therapy for metastatic castration resistant prostate cancer using cabazitaxel and prednisone	GUPCABA	I	
cabergoline	tablet	Neuro-Oncology	therapy for pituitary adenomas using cabergoline	CNCAB	I	
cabozantinib	tablet	Gastrointestinal Genitourinary Head and Neck	Treatment of Advanced Hepatocellular Carcinoma using Cabozantinib	UGICABO	R	
			Therapy for metastatic renal cell carcinoma using cabozantinib	GUCABO	I	
capecitabine	tablet	Breast	Therapy of Advanced Differentiated Thyroid Cancer using Cabozantinib	HNOTDCABO	I	
			therapy of adjuvant breast cancer using capecitabine	BRAJCAP	I	
			metastatic breast cancer as first line treatment if anthracyclines and taxanes contraindicated, or where side effect profile and/or treatment delivery concerns favour initial use of BRAVCAP; second or third line treatment of metastatic breast cancer that has previously responded to an anthracycline and taxane	BRAVCAP	I	
			therapy for metastatic breast cancer using capecitabine and lapatinib	BRAVLCAP	I	
			palliative therapy for metastatic breast cancer using trastuzumab and capecitabine	BRAVTCAP	I	
			Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and Capecitabine	UBRAVTTCAP	R	
			adjuvant therapy of colon cancer using capecitabine	GIAJCAP	I	
			adjuvant combination chemotherapy for stage III and IIB colon cancer with oxaliplatin	GIAJCAPOX	I	
			first line palliative therapy of metastatic or unresectable colorectal adenocarcinoma in a patient either not suitable for or refusing GIIRFUFA	GIAVCAP	I	
			palliative therapy of metastatic colorectal cancer using capecitabine and bevacizumab	GIAVCAPB	I	
			combined modality therapy for metastatic rectal carcinoma using capecitabine and radiation therapy	GIAVCRT	I	
			palliative therapy of metastatic neuroendocrine cancer using temozolomide and capecitabine	GIAVTZCAP	I	
			Adjuvant Therapy of Biliary Cancer using Capecitabine	GIBAJCAP	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan and capecitabine in patients unsuitable for GIIOLFIRI	GICAPIRI	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin and capecitabine	GICAPOX	I	
combination with mitomycin and radiation therapy as curative combined modality therapy for carcinoma of the anal canal	GICART	I				

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
capecitabine (cont'd)	tablet	Gastrointestinal	palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine	GICIRB	I		
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine	GICOXB	I		
			curative-intent combined modality therapy for cancer of the anal canal, using cisplatin, capecitabine and radiation therapy	GICPART	I		
			adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin and capecitabine	GIGJCOX	I		
			adjuvant chemotherapy in gastric cancer patients with completely resected gastric cancer using cisplatin and capecitabine and radiation therapy	GIGJCPRT	I		
			palliative therapy of metastatic or locally advanced anal squamous cell carcinoma using cisplatin and capecitabine	GIGAVCC	I		
			Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab	GIGAVCCT	I		
			Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin	GIGAVCOX	I		
			First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	GIGAVCOXN	I		
			First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	GIGAVCOXP	I		
			palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab	GIGAVCOXT	I		
			treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine	GIGECC	I		
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using capecitabine and gemcitabine	GIPAJCAP	I		
			second line treatment of metastatic or unresectable pancreatic adenocarcinoma using capecitabine	GIPAVCAP	I		
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin and Capecitabine	GIRAJCOX	I		
			Adjuvant Therapy for Stage II and III Rectal Cancer using Capecitabine in Patients Previously Treated with Preoperative Radiation Therapy Alone	GIRCAP	I		
			combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine and radiation therapy	GIRCRT	I		
			combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine, infusional fluorouracil and radiation therapy	GIRINFRT	I		
			Head and Neck		treatment of recurrent or metastatic squamous cell cancer of the head and neck with capecitabine	HNAVCAP	I
		treatment of recurrent or metastatic nasopharyngeal cancer with capecitabine			HNNAVCAP	I	
carboplatin	injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and trastuzumab	BRAJDCARBT	I		
			Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PAclitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab	BRAJPNCT	I		
			palliative therapy for metastatic breast cancer using cisplatin and gemcitabine	BRAVGEMP	I		
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin	BRAVPGC	I		
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PAclitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNAc	I		
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PAclitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNAcG	I		
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PAclitaxel Followed by DOXOrubicin and Cyclophosphamide	BRLACTWAC	I		

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
carboplatin (cont'd)	injectable	Breast	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	BRLACTWACG	I	
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCTAC	I	
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCWTAC	I	
		Neuro-Oncology	carboplatin and etoposide in the treatment of recurrent ependymoma	CNCARV	I	
		Gastrointestinal	First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using Carboplatin and Weekly Paclitaxel	GIAAVCT	I	
			First-Line Palliative Chemotherapy for Advanced Gallbladder or Pancreatic Carcinoma and Cholangiocarcinoma using Gemcitabine and Cisplatin	GIAVPG	I	
			neoadjuvant treatment of esophageal and gastroesophageal carcinomas using carboplatin, paclitaxel and radiation therapy	GIENACTRT	I	
		Gynecology	alternative treatment of gynecological malignancies using carboplatin and paclitaxel NAB (ABRAXANE)	GOCABR	I	
			alternative treatment of gynecological malignancies using bevacizumab, carboplatin and paclitaxel NAB (ABRAXANE)	GOCABRBEV	I	
			treatment of advanced/recurrent non-small cell cancer of the cervix with carboplatin and docetaxel	GOXCAD	I	
			primary treatment of advanced/recurrent non-small cell cancer of the cervix with carboplatin and paclitaxel	GOXCAT	I	
			primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab, carboplatin and paclitaxel	GOXCATB	I	
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab	UGOXCATBP	R	
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel, and Pembrolizumab	UGOXCATP	R	
			Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and Pembrolizumab	GOCXCPNB	I	
			Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel NAB (ABRAXANE), and Pembrolizumab	GOCXCPNP	I	
			Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using CARBOplatin and PACLitaxel	GOENAJCAT	I	
			Treatment of Advanced or Recurrent Endometrial Cancer using CARBOplatin and PACLitaxel	GOENAVCAT	I	
			treatment of primarily advanced or recurrent endometrial cancer using carboplatin and docetaxel	GOENDCAD	I	
			treatment of primary advanced or recurrent endometrial cancer using carboplatin and paclitaxel	GOENDCAT	I	
			primary treatment with visible or no visible residual tumour (moderate, high, or extreme risk) or treatment at relapse of invasive epithelial ovarian, fallopian tube, and primary peritoneal cancer, using carboplatin and docetaxel	GOOVCAD	I	
		carboplatin and gemcitabine for the treatment of recurrent platinum-sensitive ovarian cancer	GOOVCAG	I		
		first or second line therapy for invasive epithelial ovarian cancer using single-agent carboplatin	GOOVCARB	I		
		primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel	GOOVCATB	I		



**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
carboplatin (cont'd)	injectable	Gynecology	primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer, with no visible residual tumour (moderate-high risk) using carboplatin and paclitaxel	GOOVCATM	I		
			second line treatment using paclitaxel and carboplatin for epithelial ovarian cancer relapsing after primary treatment	GOOVCATR	I		
			primary treatment of visible residual (extreme risk) invasive epithelial ovarian cancer in ambulatory care settings using paclitaxel and carboplatin	GOOVCATX	I		
			primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using carboplatin and weekly paclitaxel	GOOVDDCAT	I		
			first line treatment of epithelial ovarian cancer using doxorubicin pegylated liposomal and carboplatin	GOOVPLDC	I		
			primary treatment of stage III less than or equal to 1 cm visible residual invasive epithelial ovarian cancer or stage 1 grade 3 or stage II grade 3 papillary serous ovarian cancer using intravenous and intraperitoneal paclitaxel and intraperitoneal carboplatin	GOOVIPPC	I		
			second line treatment for epithelial ovarian cancer relapsing after primary treatment using pegylated liposomal doxorubicin (PLD) and carboplatin	GOOVPLDC	I		
			treatment of small-cell gynecologic cancer with cisplatin and etoposide	GOSCPPE	I		
			treatment of small-cell gynecologic cancer with cisplatin and etoposide with radiation therapy	GOSCPERT	I		
			Genitourinary	palliative therapy for urothelial carcinoma using cisplatin and gemcitabine	GUAVPG	I	
				adjuvant therapy for stage I high risk seminoma using carboplatin	GUSCARB	I	
				therapy of genitourinary small cell tumors with a platin and etoposide	GUSCPE	I	
			Head and Neck	therapy of genitourinary small cell tumors with a platin and etoposide with radiation	GUSCPERT	I	
		treatment of advanced squamous cell carcinoma of the head and neck cancer using fluorouracil and platinum		HNAVFP	I		
		treatment for unresectable, locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin		HNAVPC	I		
		First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Paclitaxel, Carboplatin and Pembrolizumab		HNAVPCMB	I		
		treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with platinum and docetaxel		HNAVDP	I		
		treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide		HNAVPE	I		
		carboplatin	injectable	Head and Neck	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab	HNAVFPMB	I
combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck	HNLACAFRT				I		
Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent Weekly CARBOplatin and Radiation	HNLACARTW				I		
Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent 3-Weekly Carboplatin and Radiation	HNLACART3				I		
treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil	HNAVFP				I		
treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide	HNAVPE				I		
treatment of locoregionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine	HNAVPG				I		
treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin and paclitaxel	HNAVPC				I		

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES		
carboplatin (cont'd)	injectable	Lung	Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PACLitaxel	LUAJNIVPC	I			
			Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum	LUAJNIVPP	I			
			adjuvant carboplatin and paclitaxel following resection of stage I, II and IIIA non-small cell lung cancer	LUAJPC	I			
			first-line treatment of advanced non-small cell lung cancer with carboplatin and paclitaxel	LUAVPC	I			
			First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab	LUAVPCIPNI	I			
			first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel, carboplatin and pembrolizumab	LUAVPCPMB	I			
			treatment of advanced non-small cell lung cancer with platinum and gemcitabine	LUAVPG	I			
			first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab	LUAVPGPMB	I			
			first-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed	LUAVPP	I			
			First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	LUAVPPIPNI	I			
			first-line treatment of advanced non-squamous non-small cell lung cancer with platinum, pemetrexed and pembrolizumab	LUAVPPPMB	I			
			treatment of locally advanced non-small cell lung cancer using carboplatin and paclitaxel with radiation therapy	LULACATRT	I			
			treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation therapy	LULAPERT	I			
			treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy	LULAPE2RT	I			
			treatment of thymoma with cisplatin and etoposide	LUOTPE	I			
			treatment of thymoma using cisplatin and etoposide with radiation therapy	LUOTPERT	I			
			treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide	LUPUPE	I			
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide	LUSCATPE	I			
			Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide	LUSCDURPE	I			
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide	LUSCPE	I			
			Treatment of Extensive Stage Small Cell Lung Cancer with Platinum and Oral Etoposide	LUSCPEPO	I			
			Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy	LUSCPEPORT	I			
			Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide with Radiation Therapy	LUSCPERT	I			
			second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum	LUSCPI	I			
			Lymphoma	Lymphoma	Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXimab	LYDHAPR	I	
					treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	I	
			Primary Unknown	Primary Unknown	primary treatment of cancer of unknown primary origin using carboplatin and paclitaxel	PUCAT	I	
			Skin & Melanoma	Skin & Melanoma	treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide	SMMCCPE	I	
					Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. HNNOS)	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
carfilzomib	injectable	Myeloma	Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide	MYCARDEX	I	
			Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	MYCARLD	I	
			Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISACARD	R	
carmustine	injectable	Lymphoma	topical therapy in cutaneous T-cell lymphoma	LYCARTOP	I	
		Not Otherwise Specified			I	Other tumour site code followed by 'NOS' (e.g. LKNOS)
cemiplimab	injectable	Skin & Melanoma	Cemiplimab for Treatment of Cutaneous Squamous Cell Carcinoma	SMAVCEM	I	
ceritinib	capsule	Lung	treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with ceritinib	LUAVCER	I	
cetuximab	injectable	Gastrointestinal	palliative third line treatment of metastatic colorectal cancer with wild-type KRAS using cetuximab and irinotecan	GIAVCETIR	I	
		Head and Neck	combined cetuximab and radiation treatment for locally advanced squamous cell carcinoma of the head and neck	HNLACETRT	I	
		Skin & Melanoma	Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cetuximab	SMAVCET	I	
chlorambucil	tablet	Lymphoma	low grade lymphoma and chronic lymphocytic leukemia	LYCHLOR	I	
			treatment of indolent B-cell lymphoma with chlorambucil and rituximab	LYCHLRR	I	
			treatment of chronic lymphocytic leukemia with chlorambucil and rituximab	LYCLLCHLR	I	
			lymphoma palliative chemotherapy	LYPALL	I	
		Not Otherwise Specified	treatment of previously untreated chronic lymphocytic leukemia using obinutuzumab in combination with chlorambucil	LYOBCHLOR	I	
			Other tumour site code followed by 'NOS' (e.g. LKNOS, LYNOS)	I		
chlormethine	topical gel	Lymphoma	topical chlormethine in cutaneous T-Cell lymphoma	LYMECHLOR	I	
cisplatin	injectable	Breast	palliative therapy for metastatic breast cancer using cisplatin and gemcitabine	BRAVGEMP	I	
		Neuro-Oncology	adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour	CNCCV	I	
		Gastrointestinal	First-Line Palliative Chemotherapy for Advanced Gallbladder or Pancreatic Carcinoma and Cholangiocarcinoma using Gemcitabine and Cisplatin	GIAVPG	I	
			curative-intent combined modality therapy for cancer of the anal canal, using cisplatin, capecitabine and radiation therapy	GICPART	I	
			hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis	GIEMBOL	I	Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital
			palliative chemotherapy for upper gastrointestinal tract cancer (gastric, esophageal, gall bladder carcinoma and cholangiocarcinoma) and metastatic anal cancer using infusional fluorouracil and cisplatin	GIFUC	I	
			combined modality curative therapy for carcinoma of the anal canal using cisplatin, infusional fluorouracil and radiation therapy	GIFUPART	I	
			adjuvant chemotherapy of gastric cancer patients with completely resected gastric cancer using cisplatin and capecitabine and radiation therapy	GIGAJCPRT	I	
			palliative therapy of metastatic or locally advanced anal squamous cell carcinoma using cisplatin and capecitabine	GIGAVCC	I	
			Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab	GIGAVCCT	I	
			palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab	GIGAVCFT	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
cisplatin (cont'd)	injectable	Gastrointestinal	treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine	GIGECC	I		
			palliative therapy of neuroendocrine tumours using cisplatin and etoposide	GIPE	I		
		Gynecology	hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel	GIPMHIPEC	I		
			therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide and cisplatin	GOBEP	I		
			alternative treatment of gynecological malignancies using cisplatin and paclitaxel	GOCISP	I		
			Alternative Treatment of Gynecological Malignancies using Bevacizumab, Cisplatin and Paclitaxel	GOCISPBEV	I		
			treatment of high risk squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix with concurrent cisplatin and radiation	GOCXCRT	I		
			therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide	GOEP	I		
			invasive epithelial ovarian cancer	GOOVCIS	I		
			treatment of small-cell gynecologic cancer with cisplatin and etoposide	GOSCP	I		
			treatment of small-cell gynecologic cancer with cisplatin and etoposide with radiation therapy	GOSCPERT	I		
			Genitourinary	adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine	GUAJPG	I	
		palliative therapy for urothelial carcinoma using cisplatin and gemcitabine		GUAVPG	I		
		Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin		GUBDDMVAC	I		
		curative therapy for germ cell cancer using bleomycin, etoposide and cisplatin		GUBEP	I		
		treatment of locally advanced bladder cancer with weekly cisplatin and concurrent radiation		GUBPWRT	I		
		treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane		GUEDPM	I		
		therapy for nonseminoma germ cell cancer using etoposide-cisplatin		GUEP	I		
		combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation		GUFUPRT	I		
		therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin		GUMVAC	I		
		neo-adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine		GUNAJPG	I		
		therapy of genitourinary small cell tumors with a platin and etoposide		GUSCPE	I		
		therapy of genitourinary small cell tumors with a platin and etoposide with radiation		GUSCPERT	I		
		advanced therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin		GUTIP	I		
		consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna		GUVEIP	I		
		nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna		GUVIP2	I		
		Head and Neck		treatment of advanced squamous cell carcinoma of the head and neck cancer using fluorouracil and platinum	HNAVFP	I	
				palliative chemotherapy for advanced head and neck squamous cell carcinoma with weekly cisplatin	HNAV	I	
				treatment for unresectable, locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin	HNAVPC	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
cisplatin (cont'd)	injectable	Head and Neck	treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with platinum and docetaxel	HNAVPD	I		
			treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide	HNAVPE	I		
			First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab	HNAVFPMB	I		
			treatment of locally advanced (alternate) head and neck cancer using cisplatin during radiation therapy	HNLAALPRT	I		
			treatment of locally advanced squamous cell carcinoma of the head and neck with docetaxel, cisplatin and infusional fluorouracil	HNLADCF	I		
			combined chemotherapy (cisplatin) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck	HNLAPRT	I		
			treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil	HNNAVFUP	I		
			palliative chemotherapy for advanced head and neck nasopharyngeal carcinoma with weekly cisplatin	HNNAVP	I		
			treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide	HNNAVPE	I		
			treatment of locoregionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine	HNNAVPG	I		
			induction treatment of locally advanced nasopharyngeal cancer with cisplatin and gemcitabine	HNNLAPG	I		
			treatment of locally advanced nasopharyngeal cancer with concurrent cisplatin and radiation	HNNLAPRT	I		
			treatment of advanced head and neck cancer using cisplatin and fluorouracil	HNSAVFUP	I		
			treatment of advanced salivary gland cancers with cisplatin and vinorelbine	HNSAVNP	I		
			treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide	HNSAVPAC	I		
			Lung	Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum	LUAJNVPP	I	
				adjuvant cisplatin and vinorelbine following resection of non-small cell lung cancer	LUAJNP	I	
		Adjuvant Cisplatin and Pemetrexed Following Resection of Non-Small Cell Lung Cancer		LUAJPP	I		
		first-line treatment of advanced non-small cell lung cancer with cisplatin and docetaxel		LUAVDC	I		
		treatment for advanced non-small cell lung cancer with cisplatin and vinorelbine		LUAVNP	I		
		treatment of advanced non-small cell lung cancer with platinum and gemcitabine		LUAVPG	I		
		first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab		LUAVPGPMB	I		
		first-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed		LUAVPP	I		
		First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab		LUAVPPIPNI	I		
		treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation therapy		LULAPERT	I		
		treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy		LULAPE2RT	I		
		treatment of malignant mesothelioma with platinum and gemcitabine		LUMMPG	I		
		treatment of malignant mesothelioma with platinum and pemetrexed		LUMMPP	I		
		treatment of thymoma with platinum, doxorubicin and cyclophosphamide		LUOTPAC	I		
		treatment of thymoma with cisplatin and etoposide		LUOTPE	I		

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
<b>cisplatin (cont'd)</b>	injectable	Lung	treatment of thymoma using cisplatin and etoposide with radiation therapy	LUOTPERT	I		
			treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide	LUPUPE	I		
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide	LUSCATPE	I		
			Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide	LUSCDURPE	I		
			Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide	LUSCPE	I		
			Treatment of Extensive Stage Small Cell Lung Cancer with Platinum and Oral Etoposide	LUSCPEPO	I		
			Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy	LUSCPEPORT	I		
			Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide with Radiation Therapy	LUSCPERT	I		
			second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum	LUSCPI	I		
			Lymphoma	Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXimab	LYDHAPR	I	
				treatment of lymphoma with gemcitabine, dexamethasone and platinum	LYGDP	I	
				treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab	LYGDPR	I	
			Sarcoma	Treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone	LYVIPDRT	I	
				adjuvant therapy for osteosarcoma using doxorubicin and cisplatin	SAAJAP	I	
				therapy of advanced osteosarcoma using doxorubicin and cisplatin	SAAVAP	I	
Skin & Melanoma	hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal desmoplastic small round cell tumour (DSRCT)	SAHIPEC	I				
	treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide	SMMCCPE	I				
Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. HNNOS)	I				
<b>cladribine</b>	injectable	Lymphoma	hairy cell leukemia	LYCDA	I		
		Pediatric	salvage treatment of pediatric patients with Langerhans cell histiocytosis (LCH) who are risk organ positive (RO+) or with chronic reactivating disease		I		
<b>clodronate</b>	capsule	Breast	bony metastases associated with breast cancer or acute bone pain secondary to metastatic breast cancer	BRAVCLOD	I	Not reimbursed for hypercalcemia	
<b>cobimetinib</b>	tablet	Skin & Melanoma	treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib and cobimetinib	SMAVVC	I		
<b>cortisone</b>	tablet	Genitourinary	treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane	GUEDPM	I		
		Not Otherwise Specified	treatment of adrenal cortical cancer using mitotane	GUMITO	I	Other tumour site code followed by 'NOS' (e.g. GUNOS)	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
crisantaspase recombinant (RYLAZE)	injectable	Leukemia & BMT, Lymphoma	Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Adult Patients Allergic to Asparaginase (KIDROLASE) or Pegaspargase (ONCASPAR) using Crisantaspase Recombinant (RYLAZE)	LKNOS, LYONS	I	
		Pediatric	Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Pediatric Patients Allergic to Asparaginase (KIDROLASE) or Pegaspargase (ONCASPAR) using Crisantaspase Recombinant (RYLAZE) Treatment of Children with Low-Risk Acute Myeloid Leukemia Who Require Short-Acting Asparaginase per COG AAML 1831 Study using Crisantaspase Recombinant (RYLAZE)		I	
crizotinib	tablet	Lung	second-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with crizotinib	LUAVCRIZ	I	
			first-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with crizotinib	LUAVCRIZF	I	
			first-line treatment of ROS1-positive advanced non-small cell lung cancer with crizotinib	LUAVCRIZR	I	
cyclophosphamide	tablet, injectable	Leukemia & BMT	myeloablative conditioning therapy prior to autologous and allogeneic hematopoietic stem cell transplantation for myeloid malignancies using IV busulfan and cyclophosphamide	BMTIVBUCY	I	
		Breast	adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide	BRAJAC	I	
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACT	I	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACTG	I	
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTT	I	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTTG	I	
			neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel	BRAJACTW	I	
			neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and docetaxel	BRAJDAC	I	
			neoadjuvant or adjuvant therapy for breast cancer using docetaxel and cyclophosphamide	BRAJDC	I	
			adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide	BRAJFEC	I	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel	BRAJFECF	I	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRAJFECDT	I	
			neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel and cyclophosphamide	BRAJTDC	I	
			palliative therapy for metastatic breast cancer using doxorubicin and cyclophosphamide	BRAVAC	I	
			palliative therapy for advanced breast cancer using cyclophosphamide, methotrexate and fluorouracil	BRAVCMF	I	
			palliative therapy for metastatic breast cancer using metronomic low-dose oral cyclophosphamide and methotrexate	BRAVCMPO	I	
			treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel	BRLAACD	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
cyclophosphamide (cont'd)	tablet, injectable	Breast	treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRLAACDT	I		
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNAC	I		
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNACG	I		
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	BRLACTWAC	I		
			Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	BRLACTWACG	I		
			Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNAC	I		
			Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNACG	I		
			neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel followed by doxorubicin and cyclophosphamide	BRLATACG	I		
			treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel	BRLATWAC	I		
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCTAC	I		
		Gynecology	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCWTAC	I		
			palliative therapy for relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using metronomic low-dose oral cyclophosphamide.	GOOVCYCPO	I		
			therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I		
			Head and Neck	palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil	HNSAVFAC	I	
				treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide	HNSAVPAC	I	
			Lung	treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine	LUOTCAV	I	
				treatment of thymoma with platinum, doxorubicin and cyclophosphamide	LUOTPAC	I	
				treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine	LUSCCA	I	
			Lymphoma	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone	LYCHOP	I	
				treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab	LYCHOPR	I	
treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin	LYCHPBV	I					
treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab	LYCLLCVPR	I					



**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
cyclophosphamide (cont'd)	tablet, injectable	Lymphoma	treatment of Burkitt's Lymphoma and Leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I		
			advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone	LYCVP	I		
			treatment of Hodgkin's disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I		
			treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab	LYCVPR	I		
			therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia or multiple myeloma using cyclophosphamide	LYCYCLO	I		
			Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	LYDARCBD	I		
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I		
			treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab	LYFCR	I		
			lymphoma palliative chemotherapy	LYPALL	I		
			Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant	MYBOPRE	I		
			Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide	MYBORREL	I		
			Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide	MYBSD	I		
			Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide	MYCARDEX	I		
	treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide	MYDARBD	I				
	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	MYDARCBD	I				
	Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISACARD	R				
	Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISAPOMD	R				
	treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR	I				
	single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant	MYHDC	I				
	Sarcoma	tablet, injectable	Sarcoma	SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT2W	I	
				SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT3W	I	
				summary for treatment of recurrent/refractory neuroblastoma, ewing's sarcoma, osteogenic sarcoma or rhabdomyosarcoma with topotecan/cyclophosphamide	SAAVTC	I	
				treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide	SAVAC	I	
Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna				SAVACM	I		
Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide				SAVDC	I		

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
cyclophosphamide (cont'd)	tablet, injectable	Pediatric	treatment of recurrent/refractory rhabdomyosarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol		I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. BRNOS)	I	
cyclosporine	capsule	Lymphoma	cytopenias associated with lymphoproliferative disorder of large granular lymphocytes	LYCSPA	I	
			treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cyclosporine	HLHETCSPA	I	
cytarabine	injectable	Leukemia & BMT	therapy of acute myeloid leukemia using low dose cytarabine	LKAMLCYT	I	
			Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy	LKGEMOZ	I	
		Lymphoma	treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I	
			Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and rituximab	LYDHAPR	I	
		Miscellaneous Origins	treatment of lymphoma using intrathecal methotrexate and cytarabine	LYIT	I	
			treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	I	
Not Otherwise Specified	therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine	MOIT	I			
dabrafenib	capsule	Skin & Melanoma	adjuvant treatment of stage III and IV, BRAF-mutated, fully resected melanoma using dabrafenib and trametinib	SMAJDT	I	
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib	SMAVDAB	I	
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib and trametinib	SMAVDT	I	
dacarbazine	injectable	Lymphoma	treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine	LYABVD	I	
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin	LYAVDBV	I	
			Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients 60 Years or Older	LYBVAVDBV	I	
		Sarcoma	adjuvant treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine	SAAJADIC	I	
			treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine	SAAVADIC	I	
		Skin & Melanoma	high dose single agent dacarbazine for metastatic soft tissue sarcoma	SADTIC	I	
			therapy for metastatic malignant melanoma using high dose single agent dacarbazine	SMDTIC	I	
Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. SMNOS)	I			
dactinomycin	injectable	Gynecology	therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I	
			Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate	GOTDMR (previously GOTDLR)	I	
		Gynecology	Therapy for Low-Risk Gestational Trophoblastic Cancer using Dactinomycin	GOTDLRA	I	
		Sarcoma	Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide	SAVDC	I	
			Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. SANOS)	I

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
daratumumab	SC injectable only	Lymphoma	Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	LYDARCBDF	I		
	IV/SC injectable	Myeloma	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide	MYDARBD	I		
	IV/SC injectable		Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	MYDARCBDF	I		
	IV/SC injectable		Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone	MYDARLD	I		
	IV/SC injectable		Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone	MYDARLDF	I		
darolutamide	tablet	Genitourinary	Treatment of Metastatic Castration Sensitive Prostate Cancer using Darolutamide and DOCEtaxel	UGUMCSPDD	R		
			Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using Darolutamide	UGUNMPDAR	R		
dasatinib	tablet	Leukemia & BMT	treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia	LKCMLD	I		
daunorubicin	injectable	Leukemia & BMT	first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin	LKATOP	I		
		Not Otherwise Specified	Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy	LKGEMOZ	I		
					I	Other tumour site code followed by 'NOS' (e.g. KSNOS)	
daunorubicin liposomal-cytarabine liposomal (Vyxeos®)	injectable	Leukemia & BMT	Therapy of Acute Myeloid Leukemia using Daunorubicin Liposomal-Cytarabine Liposomal	LKAMLDCYT	I		
decitabine-cedazuridine	tablet	Leukemia & BMT	Therapy of Myelodysplastic Syndrome using Decitabine-Cedazuridine	ULKMDSDC	R		
degarelix	injectable	Genitourinary	therapy for prostate cancer using LHRH antagonist	GUPLHRHA	I		
denosumab (XGEVA®)	injectable	Sarcoma	neoadjuvant use in patients with non-metastatic operable giant cell tumour of the bone	SANADENO	I		
dexamethasone	tablet	Genitourinary	Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone	GUMCSPABI	I		
			Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and prednisone	UGUPABI	R		
			palliative therapy for metastatic hormone refractory prostate cancer	GUPDOC	I		
		Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE	HLHETCSPA	I		Not reimbursed for: anti-emetic treatment, steroid replacement therapy, pre-taxane use, or appetite stimulation
			treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone	LYASPMEDX	I		
			Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	LYDARCBDF	I		
			treatment of lymphoma with gemcitabine, dexamethasone and platinum	LYGDP	I		
treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab	LYGDPR	I					

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES			
dexamethasone (cont'd)	tablet	Lymphoma	Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXimab	LYDHAPR	I	Not reimbursed for: anti-emetic treatment, steroid replacement therapy, pre-taxane use, or appetite stimulation			
			lymphoma palliative chemotherapy	LYPALL	I				
		Myeloma	treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone	LYSMILE		I		
					Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone		MYBLDF	I	
					Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant		MYBLDPRE	I	
					Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant		MYBORPRE	I	
					Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide		MYBORREL	I	
					Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide		MYBSD	I	
					Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide		MYCARDEX	I	
					Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone		MYCARLD	I	
					treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide		MYDARBD	I	
					Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone		MYDARCBD	I	
					treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone		MYDARLD	I	
					Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone		MYDARLDF	I	
					Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide		UMYISACARD	R	
					treatment of previously untreated multiple myeloma and not eligible for stem cell transplant using lenalidomide with low-dose dexamethasone		UMYLDF	R	
					therapy of relapsed multiple myeloma using lenalidomide with dexamethasone		MYLDREL	I	
					treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan		MYMPBOR	I	
					therapy of multiple myeloma using pomalidomide with dexamethasone		UMYPOMDEX	R	
					Miscellaneous Origins		patients with primary or metastatic disease exhibiting cerebral edema or CNS swelling; management of malignant brain tumours; management of CNS lymphoma	MODEXA	I
								Other tumour site code followed by 'NOS' (for e.g. CNNOS)	I
		Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. BRNOS)	I					
		injectable	Not Otherwise Specified	Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and Dexamethasone on the COG AAML1331 Study	I				

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
dexrazoxane	injectable	Pediatric	Pediatric patients with acute myeloid leukemia receiving anthracycline on the COG AAML1031 protocol		I	
			Pediatric patients with neuroblastoma treated on the COG AEWS1031 protocol		I	
			Pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol		I	
			Dexrazoxane for pediatric patients with anticipated cumulative anthracycline dose >150 mg/m <sup>2</sup> or with past or anticipated radiotherapy including the pericardium (including whole-abdomen or left flank irradiation)		I	
dinutuximab	injectable	Pediatric	treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in combination with sargramostim, aldesleukin and tretinoin		I	
			high-risk neuroblastoma in first relapse or determination of refractory disease		I	
docetaxel	injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and docetaxel	BRAJDAC	I	
			neoadjuvant or adjuvant therapy for breast cancer using docetaxel and cyclophosphamide	BRAJDC	I	
			neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and trastuzumab	BRAJDCARBT	I	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel	BRAJFECD	I	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRAJFECDT	I	
			neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel and cyclophosphamide	BRAJTDC	I	
			combination with doxorubicin and cyclophosphamide as treatment of locally advanced breast cancer	BRLAACD	I	
			treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRLAACDT	I	
			first, second, or third line treatment of metastatic breast cancer patients with ECOG performance status 0, 1, or 2, and greater than 3 month life expectancy	BRAVDOC	I	
			weekly docetaxel regimen for metastatic breast cancer patients with poor tolerance to 3-weekly docetaxel regimen (BRAVDOC) or high doses of dexamethasone used in BRAVDOC	BRAVDOC7	I	
			palliative therapy for metastatic breast cancer using gemcitabine and docetaxel	BRAVGEMD	I	
			palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab and docetaxel as first-line treatment for advanced breast cancer	BRAVPTRAD	I	
			Gastrointestinal	palliative treatment of metastatic esophagogastric adenocarcinoma with docetaxel	GIAVDOC	I
		perioperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin		GIGFLODOC	I	
		combination with carboplatin as primary treatment of advanced/recurrent non-small cell cancer of the cervix in ambulatory care settings		GOCXCAD	I	
		Gynecology	treatment of primarily advanced or recurrent endometrial cancer using carboplatin and docetaxel	GOENDCAD	I	
			primary treatment with visible or no visible residual tumour (moderate, high, or extreme risk) or treatment at relapse of invasive epithelial ovarian, fallopian tube, and primary peritoneal cancer, using carboplatin and docetaxel	GOOVCAD	I	
			treatment of progressive, platinum-refractory epithelial ovarian carcinoma, primary peritoneal	GOOVDOC	I	
			combination with gemcitabine for advanced or recurrent uterine sarcoma cancer	GOSADG	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
docetaxel (cont'd)	injectable	Genitourinary	Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Gemcitabine and Docetaxel	GUBGEMDOC	I	
			Treatment of Metastatic Castration Sensitive Prostate Cancer using Darolutamide and DOCETaxel	UGUMCSPDD	R	
			Intravesical use for bladder cancer if BCG and mitomycin C not available	GUNOS	I	
			palliative therapy for metastatic hormone refractory prostate cancer	GUPDOC	I	
		Head and Neck	first-line treatment of castration sensitive, metastatic prostate cancer using docetaxel and androgen deprivation therapy with LHRH agonist or LHRH antagonist with or without antiandrogen, or surgical castration	GUPDOCADT	I	
			treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with docetaxel	HNAVDOC	I	
			treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with platinum and docetaxel	HNAVPD	I	
			treatment of locally advanced squamous cell carcinoma of the head and neck with docetaxel, cisplatin and infusional fluorouracil	HNLADCF	I	
			combination with cisplatin as first line treatment of advanced non-small lung cancer	LUAVDC	I	
			second-line treatment of non-small cell lung cancer	LUAVDOC	I	
Sarcoma	combination with gemcitabine as second or third line therapy for soft tissue sarcomas	SAAVGEMD	I			
doxorubicin	injectable	Breast	adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide	BRAJAC	I	
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACT	I	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACTG	I	
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTT	I	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTTG	I	
			neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel	BRAJACTW	I	
			neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and docetaxel	BRAJDAC	I	
			palliative therapy for metastatic breast cancer using weekly doxorubicin	BRAVA7	I	
			palliative therapy for metastatic breast cancer using doxorubicin and cyclophosphamide	BRAVAC	I	
			treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel	BRLACD	I	
			treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRLAACDT	I	
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNAC	I	
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPNACG	I	
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	BRLACTWAC	I	
			Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	BRLACTWACG	I	
			Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNAC	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
doxorubicin (cont'd)	injectable	Breast	Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNACG	I		
			neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel followed by doxorubicin and cyclophosphamide	BRLATACG	I		
			treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel	BRLATWAC	I		
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCTAC	I		
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCWTAC	I		
			Gastrointestinal	palliative therapy for hepatoma using doxorubicin	GIA	I	
				transarterial chemoembolization (TACE) of hepatocellular carcinoma using drug-eluting bead (DEB) loaded with doxorubicin	GIDEBTACE	I	
				hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis	GIEMBOL	I	Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital
				palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin	GIENDO2	I	
				hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel	GIPMHIPEC	I	
		palliative therapy for advanced adrenal cortical cancer using doxorubicin		GUAVD	I		
		Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin		GUBDDMVAC	I		
		treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane		GUEDPM	I	Not reimbursed for bladder instillations	
		therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin		GUMVAC	I		
		for use in patients with advanced endometrial cancer		GOENDD	I		
		Gynecology	Head and Neck	for use in patients with advanced uterine sarcoma	GOSAD	I	
				palliative therapy for advanced thyroid cancers using doxorubicin	HNOTAVD	I	
		Lung	Head and Neck	palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil	HNSAVFAC	I	
				treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide	HNSAVPAC	I	
				treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine	LUOTCAV	I	
			Lymphoma	treatment of thymoma with platinum, doxorubicin, and cyclophosphamide	LUOTPAC	I	
				treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine	LUSCCA	I	
				treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine	LYABVD	I	
Lymphoma	Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin	LYAVDBV	I				
	Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients 60 Years or Older	LYBVAVDBV	I				
	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone	LYCHOP	I				
treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab	LYCHOPR	I					

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
<b>doxorubicin (cont'd)</b>	injectable	Lymphoma	central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I		
			treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin	LYCHPBV	I		
			treatment of burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I		
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I		
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I		
			lymphoma palliative chemotherapy	LYPALL	I		
			Sarcoma	therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna	SAAI	I	
				3-day doxorubicin, ifosfamide and mesna for use in patients with advanced soft tissue sarcoma	SAAI3	I	
		doxorubicin for adjuvant use for patients with non-metastatic operable large high grade soft tissue sarcoma		SAAJA	I		
		adjuvant treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine		SAAJADIC	I		
		adjuvant therapy for osteosarcoma using doxorubicin and cisplatin		SAAJAP	I		
		SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma		SAALT2W	I		
		SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma		SAALT3W	I		
		therapy for advanced soft tissue sarcoma using doxorubicin		SAAVA	I		
		Not Otherwise Specified	treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine	SAAVADIC	I		
			therapy of advanced osteosarcoma using doxorubicin and cisplatin	SAAVAP	I		
treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide	SAVAC		I				
Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna	SAVACM		I				
	Other tumour site code followed by 'NOS' (e.g. BRNOS)		I	Not reimbursed for bladder instillations			
<b>doxorubicin pegylated liposomal</b>	injectable		Gynecology	Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and DOXOrubicin Pegylated Liposomal	GOOVBEVLD	I	
				first line treatment of epithelial ovarian cancer using doxorubicin pegylated liposomal and carboplatin	GOOVFPLDC	I	
				treatment of epithelial ovarian cancer relapsing after primary treatment using pegylated liposomal doxorubicin	GOOVLDOX	I	
		treatment of epithelial ovarian cancer relapsing after primary treatment using pegylated liposomal doxorubicin and carboplatin		GOOVPLDC	I		
		Kaposi's Sarcoma	KSLDO	I			
Lymphoma	LYGVLD	I					
<b>drug-eluting bead (DEB) loaded with doxorubicin (DC Bead® or HepaSphere™)</b>	other	Gastrointestinal	transarterial chemoembolization (TACE) of hepatocellular carcinoma using drug-eluting bead (DEB) loaded with doxorubicin	GIDEBTACE	I		



**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
durvalumab	injectable	Lung	treatment of locally advanced non-small cell lung cancer using durvalumab	LULADUR	I		
			treatment of locally advanced non-small cell lung cancer using 4-weekly durvalumab	LULADUR4	I		
			Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide	LUSCDURPE	I		
encorafenib	capsule	Gastrointestinal	Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer using Panitumumab and Encorafenib	UGIAPANEN	R		
		Skin & Melanoma	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Encorafenib and Binimetinib	SMAVEB	I		
enfortumab vedotin	injectable	Genitourinary	Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin	GUAVEV	I		
entrectinib	capsule	Lung	First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Entrectinib	LUAVENT	I		
		Tumour Agnostic	Treatment of Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion using Entrectinib	UTAAVENT	R		
enzalutamide	tablet	Genitourinary	Therapy for Metastatic Castration Sensitive Prostate Cancer using Enzalutamide	GUMCSPENZ	I		
			Therapy for Non-Metastatic Castration Resistant Prostate Cancer Using Enzalutamide	UGUNMPENZ	R		
			Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Enzalutamide	UGUPENZ	R		
epirubicin	injectable	Breast	adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide	BRAJFEC	I		
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel	BRAJFEC D	I		
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRAJFEC DT	I		
		Gastrointestinal	treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine	GIGECC	I		
			Genitourinary	intravesical use for bladder cancer if BCG and mitomycin C not available	GUNOS	I	
				Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. BRNOS)	I	
eribulin	injectable	Breast	Palliative Therapy for Metastatic Breast Cancer using Eribulin	BRAVERIB	I		
		Sarcoma	Palliative Therapy for Metastatic Sarcoma using Eribulin	SAAVERIB	I		
erlotinib	tablet	Lung	second or third line treatment of advanced non-small cell lung cancer maintenance therapy of advanced non-small cell lung cancer after first-line chemotherapy	LUAVERL LUAVMTNE	I I		

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
etoposide	capsule/ injectable	Neuro-Oncology	carboplatin and etoposide in the treatment of recurrent ependymoma	CNCARV	I	
			palliative treatment of patients with recurrent malignant gliomas and ependymoma using low dose etoposide	CNETO	I	
			therapy for recurrent malignant brain tumours using temozolomide and etoposide	CNTMZETO	I	
		Gastrointestinal	palliative therapy of neuroendocrine tumours using cisplatin and etoposide	GIPE	I	
			Gynecology	therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide and cisplatin	GOBEP	I
		therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide		GOEP	I	
			treatment of relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using etoposide	GOOVETO	I	
			treatment of small-cell gynecologic cancer with cisplatin and etoposide	GOSCPPE	I	
			treatment of small-cell gynecologic cancer with cisplatin and etoposide with radiation therapy	GOSCPERT	I	
			therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I	
		Genitourinary	curative therapy for germ cell cancer using bleomycin, etoposide and cisplatin	GUBEP	I	
			treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane	GUEDPM	I	
			therapy for nonseminoma germ cell cancer using etoposide-cisplatin	GUEP	I	
			therapy of genitourinary small cell tumours with a platin and etoposide	GUSCPPE	I	
			therapy of genitourinary small cell tumors with a platin and etoposide with radiation	GUSCPERT	I	
			nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna	GUVIP2	I	
		Head and Neck	treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide	HNAVPE	I	
			treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide	HNAVPE	I	
		Lung	treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation	LULAPERT	I	
			treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy	LULAPE2RT	I	
			treatment of thymoma with cisplatin and etoposide	LUOTPE	I	
			treatment of thymoma using cisplatin and etoposide with radiation therapy	LUOTPERT	I	
			treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide	LUPUPE	I	
Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide	LUSCATPE		I			
	Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide	LUSCDURPE	I			

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
<b>etoposide (cont'd)</b>	capsule/ injectable	Lung	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide	LUSCPE	I	
	capsule		Treatment of Extensive Stage Small Cell Lung Cancer with Platinum and Oral Etoposide	LUSCPEPO	I	
	capsule		Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy	LUSCPEPORT	I	
	capsule		Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide with Radiation Therapy	LUSCPERT	I	
	capsule		palliative therapy of extensive stage small cell lung cancer with oral etoposide	LUSCPOE	I	
	capsule/ injectable	Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE	HLHETCSPA	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
			treatment of burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	I	
			lymphoma palliative chemotherapy	LYPALL	I	
			treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	I	
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE	I	
			treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone	LYVIPDRT	I	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT2W	I	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT3W	I	
			3-Day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas	SAAVIME3	I	
		etoposide, ifosfamide-mesna (SAIME) for use in sarcomas	SAIME	I		
		skin & melanoma treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide	SMMCCPE	I		
		Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. HNNOS)	I		
<b>etoposide phosphate (SAP)</b>	injectable	Genitourinary	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and CISplatin	GUBEP	I	Approval from Health Canada Special Access Programme is required for each patient
			Etoposide-CISplatin Protocol for Germ Cell Cancers	GUEP	I	
			Consolidation and Salvage Therapy for Nonseminoma Using Etoposide, CISplatin, Ifosfamide, Mesna	GUVIP2	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
everolimus	tablet	Breast	therapy for advanced breast cancer using everolimus and exemestane	BRAVEVEX	I	Note: AFINITOR® DISPERZ™ formulation not funded
		Gastrointestinal	treatment of advanced neuroendocrine tumours of gastrointestinal origin (non-functional) using everolimus	UGINETEV	R	
		Genitourinary	palliative treatment of advanced pancreatic neuroendocrine tumours	GIPNEVER	I	
		Lung	therapy for advanced renal cancer using everolimus treatment of advanced neuroendocrine tumours of lung origin (non-functional) using everolimus	GUEVER LUNETEV	I I	
exemestane	tablet	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEI	R	
			neoadjuvant or adjuvant therapy for breast cancer using exemestane in postmenopausal women	BRAJEXE	I	
			Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	BRAJLHRHAI	I	
			therapy for advanced breast cancer using everolimus and exemestane	BRAVEVEX	I	
			first or second line hormonal treatment for advanced breast cancer in postmenopausal women	BRAVEXE	I	
		therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVLHRHAI	I		
Gynecology	hormonal treatment for advanced endometrial cancer in postmenopausal women	GOENDAI	I			
fedratinib	capsule	Leukemia & BMT	Treatment of Symptomatic Myelofibrosis with Fedratinib	ULKMFFED	R	
filgrastim (GRASTOFIL® or NIVESTYM®)	injectable		for inpatient administration only - see BC PharmaCare Special Authority Form for indications covered	FILGRASTIM		
fludarabine	injectable/ tablet	Leukemia & BMT		BMTNOS	I	
		Lymphoma	treatment of chronic lymphocytic leukemia or polymphocytic leukemia with fludarabine and rituximab	LKNOS	I	
			treatment of chronic lymphocytic leukemia (CLL) or polymphocytic leukemia with fludarabine, cyclophosphamide and rituximab	LYCLLFLUDR	I	
			chronic lymphocytic leukemia or low grade lymphoma	LYFCR	I	
			treatment of relapsed indolent lymphoma with fludarabine and rituximab	LYFLU	I	
			pediatric patients with AML treated on the CCG-2961 study	LYFLUDR LYNOS	I I	
Pediatric						
fludrocortisone	tablet	Genitourinary	treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane mineralocorticoid deficiency associated with mitotane use	GUEDPM GUMTO	I I	
fluorouracil	injectable	Breast	adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide	BRAJFEC	I	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel	BRAJFEC	I	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRAJFECDT	I	
			palliative therapy for advanced breast cancer using cyclophosphamide, methotrexate and fluorouracil	BRAVCMF	I	
			adjuvant combination chemotherapy for stage III and stage IIB colon cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIAJFFOX	I	
		Gastrointestinal	adjuvant therapy of colon cancer using fluorouracil injection and infusion and leucovorin infusion	GIAJFL	I	
			palliative combination chemotherapy for metastatic colorectal cancer using fluorouracil injection and infusion and folinic acid (leucovorin) infusion	GIAVFL	I	
			combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy	GIEFFOXRT	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
fluorouracil (cont'd)	injectable	Gastrointestinal	hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis	GIEMBOL	I	Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital
			palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin	GIENDO2	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab	GIFFIRB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab	GIFFIRPAN	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab	GIFFOXB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab	GIFFOXPAN	I	
			palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFIRINOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)	GIFOLFIRI	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFOLFOX	I	
			combined modality curative therapy for carcinoma of the anal canal using mitomycin, fluorouracil and radiation therapy	GIFUART	I	
			palliative chemotherapy for upper gastrointestinal tract cancer (gastric, esophageal, gall bladder carcinoma and cholangiocarcinoma) and metastatic anal cancer using infusional fluorouracil and cisplatin	GIFUC	I	
			Chemotherapy of Pseudomyxoma Peritonei Using Intraperitoneal Mitomycin and Fluorouracil	GIFUIP	I	
			combined modality curative therapy for carcinoma of the anal canal using cisplatin, infusional fluorouracil and radiation therapy	GIFUPART	I	
			adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin	GIGAJFFOX	I	
			palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab	GIGAVCFT	I	
			Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin	GIGAVFFOX	I	
			First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	GIGAVFFOXN	I	
			First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	GIGAVFFOXP	I	
			palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab	GIGAVFFOXT	I	
			perioperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin	GIGFLODOC	I	
			palliative combination chemotherapy for metastatic gastric or esophageal adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin)	GIGOLFIRI	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES		
fluorouracil (cont'd)	injectable	Gastrointestinal	hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using oxaliplatin and fluorouracil	GHIPEC	I			
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin	GIPAJFIROX	I			
			Second-Line Treatment for Metastatic Pancreatic Cancer using Irinotecan, Fluorouracil and Leucovorin	GIPAVFFIRI	I			
			Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer using Oxaliplatin, Fluorouracil and Leucovorin	GIPAVFFOX	I			
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin	GIRAJFFOX	I			
			combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine, infusional fluorouracil and radiation therapy	GIRINFRT	I			
			combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation	GUFUPRT	I			
			Head and Neck	fluorouracil and leucovorin for recurrent head and neck cancer (squamous cell carcinoma)	HNAVFUFA	I		
				treatment of advanced squamous cell carcinoma of the head and neck cancer using fluorouracil and platinum	HNAVFUP	I		
				First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab	HNAVFPFMB	I		
				combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck	HNLACAFRT	I		
				treatment of locally advanced squamous cell carcinoma of the head and neck with docetaxel, cisplatin and infusional fluorouracil	HNLADCF	I		
			Not Otherwise Specified	fluorouracil and leucovorin for recurrent head and neck cancer (nasopharyngeal)	HNAVFUFA	I		
				treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil	HNAVFUP	I		
				palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil	HNSAVFAC	I		
		treatment of advanced head and neck cancer using cisplatin and fluorouracil		HNSAVFUP	I			
		Other tumour site code followed by 'NOS' (e.g. HNNOS)		OCFU	I			
			eyedrops	Ocular	Topical Therapy for Ocular Malignancies using Fluorouracil Eye Drops	SMNOS	I	
			topical cream	Skin & Melanoma	skin cancer	SMNOS	I	
		flutamide	tablet	Genitourinary	nonsteroidal treatment of prostate cancer	GUPNSAA	I	Not reimbursed for vasomotor symptoms (hot flashes)
fulvestrant	injectable	Breast	Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	BRAVPBFLV	I			
			Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist	BRAVRBFLV	I			
gefitinib	tablet	Lung	first-line treatment of epidermal growth factor receptor mutation-positive advanced NSCLC	LUAVGEFF	I			

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
<b>gemcitabine</b>	injectable	Breast	palliative therapy for metastatic breast cancer using gemcitabine	BRAVGEM	I		
			palliative therapy for metastatic breast cancer using gemcitabine and docetaxel	BRAVGEMD	I		
			as palliative therapy for metastatic breast cancer using cisplatin and gemcitabine	BRAVGEMP	I		
			treatment of metastatic breast cancer using gemcitabine and paclitaxel	BRAVGEMT	I		
		Gastrointestinal	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin	BRAVPGC	I		
			First-Line Palliative Chemotherapy for Advanced Gallbladder or Pancreatic Carcinoma and Cholangiocarcinoma using Gemcitabine and Cisplatin	GIAVPG	I		
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using capecitabine and gemcitabine	GIPAJGCAP	I		
			adjuvant chemotherapy for pancreatic adenocarcinoma using gemcitabine	GIPAJGEM	I		
			palliative chemotherapy for pancreatic adenocarcinoma, gallbladder cancer, and cholangiocarcinoma using gemcitabine	GIPGEM	I		
			first line treatment of locally advanced and metastatic pancreatic cancer with paclitaxel NAB (ABRAXANE) and gemcitabine	GIPGEMABR	I		
			Gynecology	Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine	GOOVBEVG	I	
				carboplatin and gemcitabine for the treatment of recurrent platinum-sensitive ovarian cancer	GOOVCAG	I	
				palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer using gemcitabine	GOOVGEM	I	
				combination with docetaxel for advanced or recurrent uterine sarcoma cancer	GOSADG	I	
		Genitourinary	adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine	GUAJPG	I		
			combination with cisplatin for advanced transitional cell carcinoma of the bladder	GUAVPG	I		
			intravesical therapy for non-muscle invasive bladder cancer using gemcitabine	GUBGEM	I		
			Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Gemcitabine and Docetaxel	GUBGEMDOC	I		
			combination with cisplatin as neoadjuvant therapy for urothelial carcinoma	GUNAJPG	I		
			palliative therapy for germ cell cancers using paclitaxel and gemcitabine	GUTAXGEM	I		
Head and Neck	treatment of loco-regionally recurrent and/or metastatic nasopharyngeal cancer with gemcitabine	HNAVPGEM	I				
	treatment of local-regionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine	HNAVPG	I				

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
<b>gemcitabine (cont'd)</b>	injectable	Head and Neck	as induction treatment of locally advanced nasopharyngeal cancer with cisplatin and gemcitabine	HNNLAPG	I	
		Lung	combination with cisplatin or carboplatin as treatment of advanced non-small cell lung cancer	LUAVPG	I	
			first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab	LUAVPGPMB	I	
			treatment of malignant mesothelioma with platinum and gemcitabine	LUMMPG	I	
		Lymphoma	treatment of lymphoma with gemcitabine, dexamethasone and platinum	LYGDP	I	
			treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab	LYGDP	I	
			Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	LYGEMOXPEG	I	
			Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and Doxorubicin Pegylated Liposomal	LYGULD	I	
			palliative chemotherapy of lymphomas	LYPALL	I	
			Pediatric	treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)		I
	Sarcoma	combination with docetaxel as second or third line therapy for soft tissue sarcomas	SAAVGEMD	I		
<b>gemtuzumab ozogamicin</b>	injectable	Leukemia & BMT	Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy	LKGEMOZ	I	
		Pediatric	Pediatric patients with de novo acute myeloid leukemia (AML) in the first induction chemotherapy cycle, in combination with standard chemotherapy		R	
<b>gilteritinib</b>	tablet	Leukemia & BMT	Therapy of Relapsed or Refractory FLT3+ Acute Myeloid Leukemia using Gilteritinib	ULKAMLGIL	R	
<b>goserelin</b>	long acting injectable	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEI	R	
			Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	UBRAJABET	R	
			Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	BRAJLHRHAI	I	
			neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen	BRAJLHRHT	I	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVLHRHAI	I	
			combination therapy with tamoxifen palliative therapy for metastatic breast cancer	BRAVLHRHT	I	
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	BRAVPALAI	I	Not reimbursed for endometriosis
			Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	BRAVPBFLV	I	
			Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist	BRAVRBFLV	I	
			therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist	BRAVRIBAI	I	
	Genitourinary	therapy for prostate cancer using LHRH agonist	GUPLHRH	I		
<b>hydrocortisone</b>	tablet, injectable	Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE	HLHETCSPA	I	
		Not Otherwise Specified			I	Other tumour site code followed by 'NOS' (e.g. LYDOS)
<b>hydroxyurea</b>	capsule	Leukemia & BMT	Myeloid neoplasms, including but not limited to: Acute myeloid leukemia, Myelodysplastic syndromes (e.g. Refractory anemia), Myeloproliferative disease (e.g. Chronic myeloid leukemia, Polycythemia, Essential thrombocythemia)	LKNOS	I	
<b>hydroxyurea (cont'd)</b>	capsule	Lymphoma	Lymphoid neoplasms, including but not limited to: Lymphoproliferative disease, Myeloma	LYNOS	I	
<b>ibrutinomab tiuxetan 90Y (ZEVALIN®)</b>	injectable	Lymphoma	Palliative Therapy For Lymphoma Using Radioimmunotherapy: ritUXimab-Priming for 90Y-Ibrutinomab tiuxetan (ZEVALIN®)	LYRITZ	I	



**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
ibrutinib	capsule	Lymphoma	treatment of previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma using ibrutinib	LYFIBRU	I	
			treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using ibrutinib	LYIBRU	I	
			treatment of relapsed/refractory mantle-cell lymphoma using ibrutinib	LYMIBRU	I	
idarubicin	injectable	Not Otherwise Specified		Tumour site code followed by 'NOS' (e.g. BRNOS)	I	
		Pediatric	Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and Dexamethasone on the COG AAML 1331 Study		I	
idelalisib	tablet	Lymphoma	treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab	LYIDELAR	I	
ifosfamide	injectable	Genitourinary	advanced therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin	GUTIP	I	
			consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna	GUVEIP	I	
			nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna	GUVIP2	I	
		Lymphoma	treatment of burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	I	
			treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	I	
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE	I	
			treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone	LYVIPDRT	I	
		Pediatric	treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)		I	
		Sarcoma	therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna	SAAI	I	
			3-day doxorubicin, ifosfamide and mesna for use in patients with advanced soft tissue sarcoma	SAAI3	I	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or	SAALT2W	I	
			Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or	SAALT3W	I	
			Rhabdomyosarcoma therapy for advanced soft tissue sarcoma using ifosfamide	SAAVI	I	
3-day ifosfamide for use in patients with advanced soft tissue sarcoma	SAAVI3		I			
	3-Day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas	SAAVIME3	I			
	etoposide, ifosfamide-mesna (SAIME) for use in sarcomas	SAIME	I			

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
ifosfamide (cont'd)	injectable	Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I	
imatinib	tablet	Leukemia & BMT	therapy for chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia	LKCM1	I	
		Pediatric	pediatric patients with Philadelphia chromosome positive acute lymphoblastic leukemia		I	
		Sarcoma	adjuvant therapy of C-Kit positive high risk gastrointestinal stromal cell tumours	SAAJGI	I	
			advanced c-kit positive and c-kit negative gastrointestinal stromal cell tumours	SAAVGI	I	
			advanced c-kit positive gastrointestinal stromal cell tumors using 800 mg dosing of imatinib	SAAVGIDD	I	
Skin & Melanoma	treatment of advanced c-kit melanoma using imatinib	SMAVI	I			
imiquimod	topical cream	Skin & Melanoma	topical immunotherapy for in-transit melanoma metastases, cutaneous lymphoma, basal cell carcinoma using imiquimod	SMIMI	I	
inotuzumab ozogamicin	injectable	Leukemia & BMT	treatment of relapsed or refractory pre-B-cell acute lymphoblastic leukemia with inotuzumab ozogamicin	ULKINOZ	R	
ipilimumab	injectable	Genitourinary	treatment of metastatic or advanced renal cell carcinoma using ipilimumab and nivolumab	GUAVIPNI	I	
		Lung	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab	LUAVPCIPNI	I	
			First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	LUAVPPIPNI	I	
			Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab	LUMMIPNI	I	
			Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab	LUMMIPNI3	I	
		Skin & Melanoma	Treatment of Unresectable or Metastatic Melanoma Using Alternative Dosing Regimen of Ipilimumab and Nivolumab	SMAVALIPNI	I	
			first-line treatment of unresectable or metastatic melanoma using ipilimumab	SMAVFIPI	I	
			treatment of advanced and metastatic melanoma after prior systemic therapy	SMAVIPI	I	
treatment of unresectable or metastatic melanoma using ipilimumab and nivolumab	SMAVIPNI		I			
irinotecan	injectable	Gastrointestinal	palliative third line treatment of metastatic colorectal cancer with wild-type KRAS using cetuximab and irinotecan	GIAVCETIR	I	
			Palliative Therapy of Metastatic Colorectal Cancer using Irinotecan and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	GIAVRALIR	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan and capecitabine in patients unsuitable for GEOFIRI	GICAPIRI	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine	GICIRB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab	GIFFIRB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab	GIFFIRPAN	I	
			palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFIRINOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)	GIFOLFIRI	I	
			second line palliative combination chemotherapy for metastatic gastric or esophageal adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin)	GIGOLFIRI	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
<b>irinotecan (cont'd)</b>	injectable	Gastrointestinal	palliative chemotherapy of metastatic colorectal cancer using irinotecan	GIIR	I	
			palliative therapy of metastatic colorectal cancer in patients who may not tolerate the 3-weekly irinotecan schedule of GIIR	GIIRINALT	I	
		Lung	adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin	GIPAJFIROX	I	
			Second-Line Treatment for Metastatic Pancreatic Cancer using Irinotecan, Fluorouracil and Leucovorin	GIPAVFFIRI	I	
			second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum	LUSCPI	I	
			pediatric patients treated on the COG protocol ARST0531 for intermediate-risk rhabdomyosarcoma		I	
			pediatric patients with recurrent pediatric neuroblastoma treated on the COG protocol ANBL0421		I	
			pediatric patients with high risk renal tumors treated on the COG protocol AREN0321		I	
			pediatric patients with high risk rhabdomyosarcoma treated on the COG protocol ARST0431		I	
			pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol		I	
pediatric patients with recurrent/refractory medulloblastomas/CNS PNET of childhood treated on the COG ACNS0821 protocol		I				
<b>isatuximab</b>	injectable	Myeloma	Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISACARD	R	
			Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISAPOMD	R	
<b>isotretinoin</b>	capsule	Pediatric	pediatric patients with high risk neuroblastoma		I	
			pediatric patients treated on the COG protocol ACNS0332 for above average risk medulloblastoma/PNE		I	
<b>lanreotide</b>	injectable	Neuro-Oncology	treatment of growth hormone secreting pituitary adenoma using lanreotide	CNLAN	I	
		Gastrointestinal	symptomatic management of functional carcinoid and neuroendocrine tumours of the GI Tract using lanreotide	UGILAN	R	
<b>lapatinib</b>	tablet	Breast	therapy for metastatic breast cancer using capecitabine and lapatinib	BRAVLCAP	I	
<b>larotrectinib</b>	capsule, oral solution	Tumour Agnostic	Treatment of Solid Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion using Larotrectinib	UTAAVLAR	R	
		Pediatric	Treatment of Solid Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion using Larotrectinib		R	
<b>lenalidomide</b>	capsule	Leukemia & BMT	therapy of myelodysplastic syndrome using lenalidomide	LKMDSL	I	
		Myeloma	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone	MYBLDF	I	
			Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant	MYBLDPRE	I	
			Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	MYCARLD	I	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone	MYDARLD	I	
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone	MYDARLDF	I	
			treatment of previously untreated multiple myeloma and not eligible for stem cell transplant using lenalidomide with low-dose dexamethasone	UMYLDF	R	
			therapy of relapsed multiple myeloma using lenalidomide with dexamethasone	MYLDREL	I	
			Maintenance Therapy of Multiple Myeloma using Lenalidomide	MYLENMTN	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
lenvatinib	capsule	Gastrointestinal	Therapy of Advanced Hepatocellular Carcinoma using Lenvatinib	GILEN	I	
		Gynecology	Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using Pembrolizumab and Lenvatinib	GOENDAVPL	I	
			Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using 6-weekly Pembrolizumab and Lenvatinib	GOENDAVPL6	I	
		Genitourinary	Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Lenvatinib	GUAVPEML	I	
			Treatment of Metastatic Renal Cell Carcinoma using 6-weekly Pembrolizumab and Lenvatinib	GUAVPEML6	I	
		Head and Neck	therapy for locally recurrent or metastatic, RAI-refractory differentiated thyroid cancer using lenvatinib	HNOTLEN	I	
letrozole	tablet	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEAI	R	
			neoadjuvant or adjuvant therapy for breast cancer using letrozole in postmenopausal women	BRAJLET	I	
			Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer	BRAJLHRHAI	I	
			first or second line hormonal treatment for advanced breast cancer in postmenopausal women	BRAVLET	I	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAVLHRHAI	I	
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	BRAVPALAI	I	
			therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist	BRAVRIBAI	I	
		Gynecology	hormonal treatment for advanced endometrial cancer in postmenopausal women with contraindications to tamoxifen or intolerant of tamoxifen	GOENDAI	I	
			hormonal treatment for advanced ovarian cancer in postmenopausal women	GOOVAI	I	
leucovorin calcium	tablet, injectable	Breast	treatment of meningeal disease using high-dose methotrexate with leucovorin rescue	BRAVHDMTX	I	
			Gastrointestinal	adjuvant combination chemotherapy for Stage III and Stage IIB colon cancer using oxaliplatin, fluorouracil and folinic acid (Leucovorin)	GIAJFFOX	I
		adjuvant therapy of colon cancer using fluorouracil injection and infusion and leucovorin infusion		GIAJFL	I	
		palliative combination chemotherapy for metastatic colorectal cancer using fluorouracil injection and infusion and folinic acid (leucovorin) infusion		GIAVFL	I	
		combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy		GIEFFOXRT	I	
		palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab		GIFFIRB	I	
		palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab		GIFFIRPAN	I	
		palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab		GIFFOXB	I	
		palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab		GIFFOXPAN	I	
		palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)		GIFIRINOX	I	
		palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)		GIFOLFIRI	I	
		palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin)		GIFOLFOX	I	
		adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin		GIGAJFFOX	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
leucovorin calcium (cont'd)	tablet, injectable	Gastrointestinal	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin	GIGAVFFOX	I		
			First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	GIGAVFFOXN	I		
			First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	GIGAVFFOXP	I		
			palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab	GIGAVFFOXT	I		
			peroperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin	GIGFLODOC	I		
			palliative combination chemotherapy for metastatic gastric or esophageal adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin)	GIGFOLFIRI	I		
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin	GIPAJFIROX	I		
			Second-Line Treatment for Metastatic Pancreatic Cancer using Irinotecan, Fluorouracil and Leucovorin	GIPAVFFIRI	I		
			Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer using Oxaliplatin, Fluorouracil and Leucovorin	GIPAVFFOX	I		
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin	GIRAJFFOX	I		
			therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I		
			Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate	GOTDMR (previously GOTDLR)	I		
			Head and Neck	fluorouracil and leucovorin for recurrent head and neck cancer (squamous cell carcinoma)	HNAVFUFA	I	
				fluorouracil and leucovorin for recurrent head and neck cancer (nasopharyngeal)	HNNAVFUFA	I	
		Lymphoma	treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone	LYASPMEDEX	I		
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I		
			treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I		
			Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide	LYHDMRTEM	I		
			treatment of natural killer or T-Cell lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE	I		
			Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. LYNOS)	I		

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
leuprolide	long acting injectable	Breast	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	UBRAJABEI	R	Not reimbursed for endometriosis. Leuprolide acetate IM (LUPRON®) and SC (ELIGARD®) injectables are both reimbursable for prostate cancer indications (GUPLHRH).
			Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	UBRAJABET	R	
			Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen	BRAJLHRHAI	I	
			therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor	BRAJLHRHT	I	
			combination therapy with tamoxifen palliative therapy for metastatic breast cancer	BRAVLHRHAI	I	
			therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist	BRAVLHRHT	I	
			Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	BRAVPALAI	I	
			Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist	BRAVPBFLV	I	
			therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist	BRAVRBFLV	I	
			therapy for prostate cancer using LHRH agonist	BRAVRIBAI	I	
		Genitourinary		GUPLHRH	I	
lomustine	capsule	Neuro-Oncology	lomustine for treatment of recurrent malignant brain tumors	CNCCNU	I	
			adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour	CNCCV	I	
			modified PCV chemotherapy of brain tumours using procarbazine, lomustine and vincristine	CNMODPCV	I	
			lymphoma palliative chemotherapy	LYPALL	I	
		Lymphoma		Other tumour site code followed by 'NOS' (e.g. CNNOS)	I	
		Not Otherwise Specified				
<sup>177</sup> Lu-Dotatate	radio-pharmaceutical	Gastrointestinal	Peptide Receptor Radionuclide Therapy (PRRT) using <sup>177</sup> Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours	UGIPRRT	R	
medroxyprogesterone	tablet	Gynecology	non-aromatase inhibitor hormonal treatment of endometrial cancer	GOENDH	I	Not reimbursed for appetite stimulation or replacement therapy.
megestrol	tablet	Breast	breast cancer	BRAVMEG	I	Not reimbursed for appetite stimulation or symptom management
		Gynecology	non-aromatase inhibitor hormonal treatment of endometrial cancer	GOENDH	I	
melphalan	tablet, injectable	Leukemia & BMT Myeloma	conditioning therapy for autologous stem cell transplant using high dose melphalan in the treatment of multiple myeloma	BMTMM0301	I	
			Treatment of Multiple Myeloma using Melphalan and Prednisone	MYMP	I	
			treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR	I	
				Other tumour site code followed by 'NOS' (e.g. LKNOS)	I	
		Not Otherwise Specified		Tumour site code followed by 'NOS' (e.g. LKNOS)	I	
6-mercaptopurine	tablet	Not Otherwise Specified				

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
mesna	injectable	Genitourinary	therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin (TIP)	GUTIP	I	Approved for use ONLY as an uro-protector for ifosfamide or high dose cyclophosphamide
			consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna	GUVEIP	I	
			nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna	GUVIP2	I	
		Lymphoma	Treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	I	
			treatment of relapsed or refractory advanced stage aggressive B-Cell Non-Hodgkin's Lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	I	
			treatment of Natural Killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE	I	
			treatment of newly diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone	LYVIPDRT	I	
			treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)		I	
		Sarcoma	therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna	SAAI	I	
			3-day doxorubicin, ifosfamide and mesna for use in patients with advanced soft tissue sarcoma	SAAI3	I	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT2W	I	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT3W	I	
			therapy for advanced soft tissue sarcoma using ifosfamide	SAAVI	I	
			3-day ifosfamide for use in patients with advanced soft tissue sarcoma	SAAVI3	I	
			3-day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas	SAAVIME3	I	
			etoposide, ifosfamide-mesna (SAIME) for use in sarcomas	SAIME	I	
			Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna	SAVACM	I	
mesna dosage modification for hematuria secondary to oxazaphosphorines	SCMESNA		I			
Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. SANOS)	I				
methotrexate	tablet, injectable	Breast	palliative therapy for advanced breast cancer using cyclophosphamide, methotrexate and fluorouracil	BRAVCMF	I	
			treatment of meningeal disease using high-dose methotrexate with leucovorin rescue	BRAVHDMTX	I	
		Gynecology	therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I	
			Therapy for Low-Risk Gestational Trophoblastic Cancer using Methotrexate	GOTDLRM	I	
			Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate	GOTDMR (previously GOTDLR)	I	
		Genitourinary	Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin	GUBDDMVAC	I	
			therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin	GUMVAC	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
<b>methotrexate (cont'd)</b>	tablet, injectable	Head and Neck	treatment of head and neck cancer using methotrexate as standard therapy	HNAVMM	I	
			therapy for Kaposi's Sarcoma using vinblastine-vincristine	KSVB	I	
		Lymphoma	treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE	HLHETCSPA	I	
			treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone	LYASPMEDX	I	
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I	
			treatment of burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
			Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide	LYHDMRTEM	I	
			Central Nervous System Prophylaxis with High-Dose Methotrexate in Diffuse Large B-Cell Lymphoma	LYHDMTXPRO	I	
			treatment of lymphoma using intrathecal methotrexate and cytarabine	LYIT	I	
			treatment of Burkitt's Lymphoma and Leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	I	
			lymphoma palliative chemotherapy	LYPALL	I	
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE	I	
Miscellaneous Origins	therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine	MOIT	I			
Sarcoma	palliative therapy for aggressive fibromatosis using weekly or alternate week methotrexate and vinblastine intravenously	SAMV	I			
Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. MYNOS)	I			
<b>methoxsalen</b>	injectable	Lymphoma	Treatment of Cutaneous T-Cell Lymphoma (Sézary Syndrome) with Extracorporeal Photopheresis	LYMFECF	I	
<b>methyl aminolevulinate (METVIX®)</b>	topical cream	Skin & Melanoma	topical therapy for skin cancer with PDT (Photodynamic Therapy)	SMPDT	I	Only reimbursable when prescribed by physicians in the Skin Tumour Group within the Skin PDT Program of the BC Cancer Agency
<b>midostaurin</b>	capsule	Leukemia & BMT	therapy of FLT3+ acute myeloid leukemia using midostaurin in combination with induction and consolidation chemotherapy	LKAMLMIDO	I	
<b>mitomycin</b>	injectable	Gastrointestinal	combined modality therapy for carcinoma of the anal canal using mitomycin, capecitabine and radiation therapy	GICART	I	
			hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis	GIEMBOL	I	Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital
			combined modality curative therapy for carcinoma of the anal canal using mitomycin, fluorouracil and radiation therapy	GIFUART	I	
			chemotherapy of pseudomyxoma peritonei using intraperitoneal mitomycin and fluorouracil	GIFUIP	I	
			hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using oxaliplatin and fluorouracil	GIHIPEC	I	
		Genitourinary	combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation	GUFUPRT	I	



**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
mitomycin (cont'd)	injectable	Genitourinary	intravesical therapy for non-muscle invasive cell bladder cancer using mitomycin	GUBMITO	I	
	eye drops	Ocular	eye drops as topical therapy for ocular malignancies	OCMITO	I	
	injectable	Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. GUNOS)	I	
mitotane	tablet	Genitourinary	treatment of advanced adrenal cortical cancer	GUMITO	I	
			treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane	GUEDPM	I	
mitoxantrone	injectable	Genitourinary	palliative therapy for hormone-refractory prostate cancer using mitoxantrone and prednisone	GUPMX	I	
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. BRNOS)	I	
nilotinib	tablet	Leukemia & BMT	Treatment of Chronic Myeloid Leukemia using Nilotinib	LKCMLN	I	
nilutamide	tablet	Genitourinary	prostate carcinoma patients who are intolerant to bicalutamide or flutamide, at 150 mg po daily	GUPNSAA	I	Not reimbursed for vasomotor symptoms (hot flashes)
niraparib	capsule	Gynecology	Maintenance Treatment of Newly Diagnosed Platinum Responsive Epithelial Ovarian Cancer using Niraparib	GOOVNIRM	I	
			Maintenance Treatment of Relapsed Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Niraparib	GOOVNIRAM	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
nivolumab	injectable	Gastrointestinal	Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer using Nivolumab	GIAJNIV	I		
			First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	GIGAVCOXN	I		
			First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	GIGAVFFOXN	I		
		Genitourinary	Adjuvant Treatment of Resected Urothelial Carcinoma using Nivolumab	UGUAJNIV	R		
			Adjuvant Treatment of Resected Urothelial Carcinoma using 4-Weekly Nivolumab	UGUAJNIV4	R		
			treatment of metastatic or advanced renal cell carcinoma using ipilimumab and nivolumab	GUAVIPNI	I		
			treatment of metastatic or advanced renal cell carcinoma using nivolumab	GUAVNIV	I		
			treatment of metastatic or advanced renal cell carcinoma using 4-weekly nivolumab	GUAVNIV4	I		
			Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using Nivolumab	HNAVNIV	I		
		Head and Neck	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab	HNAVNIV4	I		
			Lung	Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PACLitaxel	LUAJNIVPC	I	
		Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum		LUAJNIVPP	I		
		treatment of advanced non-small cell lung cancer using nivolumab		LUAVNIV	I		
		treatment of advanced non-small cell lung cancer using 4-weekly nivolumab		LUAVNIV4	I		
		First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab		LUAVPCIPNI	I		
		First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab		LUAVPPIPNI	I		
		Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab		LUMMIPNI	I		
		Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab		LUMMIPNI3	I		
		Lymphoma		treatment of relapsed or refractory Hodgkin lymphoma using nivolumab	LYNIV	I	
				treatment of relapsed or refractory Hodgkin lymphoma using 4-weekly nivolumab	LYNIV4	I	
		Skin & Melanoma	adjuvant treatment of resected stage III-IV NED melanoma using nivolumab	SMAJNIV	I		
			adjuvant treatment of resected stage III-IV NED melanoma using 4-weekly nivolumab	SMAJNIV4	I		
			Treatment of Unresectable or Metastatic Melanoma Using Alternative Dosing Regimen of Ipilimumab and Nivolumab	SMAVALIPNI	I		
treatment of unresectable or metastatic melanoma using ipilimumab and nivolumab	SMAVIPNI		I				
treatment of unresectable or metastatic melanoma using nivolumab	SMAVNIV		I				
treatment of unresectable or metastatic melanoma using 4-weekly nivolumab	SMAVNIV4		I				
obinutuzumab	injectable	Lymphoma	treatment of previously untreated chronic lymphocytic leukemia using obinutuzumab in combination with chlorambucil	LYOBCHLOR	I		
			treatment of rituximab-refractory follicular lymphoma with obinutuzumab in combination with bendamustine	LYOBBEND	I		
			Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Obinutuzumab	LYVENOB	I		

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
octreotide	short acting injectable	Neuro-Oncology	treatment of growth hormone secreting pituitary adenoma	CNNOS	I	
		Gastrointestinal	management of non-functional neuroendocrine tumours of the GI tract; symptomatic management of functional carcinoid and neuroendocrine tumours of the GI tract	GINOS	I	
	long acting injectable	Neuro-Oncology	Treatment of Growth Hormone Secreting Pituitary Adenoma using Octreotide Long Acting	CNOCTLAR	I	
		Gastrointestinal	Management of Non-Functional Neuroendocrine Tumours of the GI Tract using Octreotide Long Acting Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumors of the GI Tract using Octreotide Long Acting	GINFOCLAR GIOCTLAR	I I	
olaparib	tablet	Breast	Treatment of BRCA-Mutated High-Risk Early Breast Cancer using Olaparib	UBRAJOLA	R	
		Genitourinary	Metastatic Castration-Resistant Prostate Cancer using Olaparib	UGUPOLAP	R	
		Gynecology	Maintenance Treatment of Newly Diagnosed BRCA-Mutated Platinum Responsive Epithelial Ovarian Cancer using Olaparib	GOOVFOLAM	I	
			Maintenance Treatment of Relapsed, BRCA-Mutated, Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Olaparib	GOOVOLAPM	I	
osimertinib	tablet	Lung	Adjuvant Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) with Osimertinib	LUAJOSI	I	
			treatment of EGFR T790M mutation-positive advanced non-small cell lung cancer with osimertinib	LUAVOSI	I	
			first-line treatment of EGFR mutation-positive advanced non-small cell lung cancer with osimertinib	LUAVOSIF	I	
oxaliplatin	injectable	Gastrointestinal	adjuvant combination chemotherapy for stage III and IIB colon cancer with capecitabine	GIAJCAPOX	I	
			adjuvant combination chemotherapy for stage III and IIB colon cancer with fluorouracil and folinic acid	GIAJFFOX	I	
			adjuvant combination chemotherapy for node-positive colon cancer using oxaliplatin and raltitrexed in patients intolerant to fluorouracil or capecitabine	GIAJRALOX	I	
			Palliative Therapy of Metastatic Colorectal Cancer using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	GIAVRALOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin and capecitabine	GICAPOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine	GICOXB	I	
			combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy	GIEFFOXRT	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab	GIFFOXB	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab	GIFFOXPAN	I	
			palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)	GIFIRINOX	I	
			palliative combination chemotherapy for metastatic colorectal cancer with fluorouracil and folinic acid	GIFOLFOX	I	
			adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin and capecitabine	GIGAJCOX	I	
			adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin	GIGAJFFOX	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
oxaliplatin (cont'd)	injectable	Gastrointestinal	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin	GIGAVCOX	I	
			First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	GIGAVCOXN	I	
			First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	GIGAVCOXP	I	
			palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab	GIGAVCOXT	I	
			Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin	GIGAVFFOX	I	
			First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	GIGAVFFOXN	I	
			First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	GIGAVFFOXP	I	
			palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab	GIGAVFFOXT	I	
			perioperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin	GIGFLODOC	I	
			hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using oxaliplatin and fluorouracil	GHIPEC	I	
			adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin	GIPAJFIROX	I	
			Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer using Oxaliplatin, Fluorouracil and Leucovorin	GIPAVFFOX	I	
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin and Capecitabine	GIRAJCOX	I	
			Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin	GIRAJFFOX	I	
		Lymphoma		Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	LYGEMOXPEG	I

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
paclitaxel	injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACT	I	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel	BRAJACTG	I	
			neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTT	I	
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTTG	I	
			neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel	BRAJACTW	I	
			adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab	BRAJTTW	I	
			treatment of metastatic breast cancer using gemcitabine and paclitaxel	BRAVGEMT	I	
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with PACLitaxel	BRAVPP	I	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Paclitaxel as First-Line Treatment for Advanced Breast Cancer	BRAVPTRAT	I	
			palliative therapy for metastatic breast cancer using paclitaxel	BRAVTAX	I	
			palliative therapy for metastatic breast cancer using weekly paclitaxel (given weekly for 3 weeks out of 4 weeks) (replaces BRAVT7)	BRAVTW	I	
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	BRLACTWAC	I	
			Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	BRLACTWACG	I	
		neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel followed by doxorubicin and cyclophosphamide	BRLATACG	I		
		treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel	BRLATWAC	I		
		NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCTAC	I		
		NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCWTAC	I		
		Gastrointestinal	First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using Carboplatin and Weekly Paclitaxel	GIAAVCT	I	
		neoadjuvant treatment of esophageal and gastroesophageal carcinomas using carboplatin, paclitaxel and radiation therapy	GIENACTRT	I		
		second-line therapy for metastatic or locally advanced gastric or gastroesophageal junction cancer using weekly paclitaxel and ramucirumab	GIGAVRAMT	I		
		hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel	GIPMHIPEC	I		
		Gynecology	alternative treatment of gynecological malignancies using cisplatin and paclitaxel	GOCISP	I	
		Alternative Treatment of Gynecological Malignancies using Bevacizumab, Cisplatin and Paclitaxel	GOCISPBEV	I		
combination with carboplatin as primary treatment of advanced/recurrent non-small cell cancer of the cervix in ambulatory care settings	GOCXCAT	I				
Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using CARBOplatin and PACLitaxel	GOENAJCAT	I				
Treatment of Advanced or Recurrent Endometrial Cancer using CARBOplatin and PACLitaxel	GOENAVCAT	I				

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
paclitaxel (cont'd)	injectable	Gynecology	primarily advanced or recurrent endometrial cancer	GOENDCAT	I		
			primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel	GOOVCATB	I		
			primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer, with no visible residual tumour (moderate-high risk) ovarian cancer relapsing after complete remission of at least 4 months' duration in response to primary treatment with carboplatin and paclitaxel	GOOVCATM	I		
			primary treatment of visible residual (extreme risk) invasive epithelial ovarian cancer	GOOVCATR	I		
			primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab, carboplatin and paclitaxel	GOOVCATX	I		
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab	GOCXCATB	I		
			Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel, and Pembrolizumab	UGOCXCATBP	R		
			Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel	UGOCXCATP	R		
			primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using carboplatin and weekly paclitaxel	GOOVBEVP	I		
			primary treatment of stage III less than or equal to 1 cm visible residual invasive epithelial ovarian cancer using intravenous and intraperitoneal paclitaxel and intraperitoneal carboplatin	GOOVDDCAT	I		
			progressive, platinum-refractory ovarian carcinoma, primary peritoneal carcinoma or fallopian tube carcinoma	GOOVIPP	I		
			Genitourinary	palliative therapy for germ cell cancers using paclitaxel and gemcitabine	GOOVTAX3	I	
				advanced therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin	GUTAXGEM	I	
				GUTIP	I		
		Head and Neck	treatment for unresectable, locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin	HNAVPC	I		
			First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Paclitaxel, Carboplatin and Pembrolizumab	HNAVPCPMB	I		
		Lung	treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin and paclitaxel	HNNAVPC	I		
			Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PACLitaxel	LUAJNIVPC	I		
			adjuvant carboplatin and paclitaxel following resection of stage I, II and IIIA non-small cell lung cancer	LUAJPC	I		
			combination with carboplatin as first line treatment of advanced non-small cell lung cancer	LUAVPC	I		
			First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab	LUAVPCIPNI	I		
			first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel, carboplatin and pembrolizumab	LUAVPCPMB	I		
			treatment of locally advanced non-small cell lung cancer using carboplatin and paclitaxel with radiation therapy	LULACATRT	I		
Primary Unknown	primary treatment of cancer of unknown primary origin using carboplatin and paclitaxel		PUCAT	I			
	treatment of recurrent or resistant pediatric malignant germ cell tumors with paclitaxel, ifosfamide and carboplatin (COG protocol AGCT0521)			I			
Sarcoma	Metastatic or Unresectable Angiosarcoma using Weekly Paclitaxel (3 Weeks out of 4 Weeks Schedule)		SAAVTW	I			

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
paclitaxel NAB (ABRAXANE)	injectable	Breast	Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE)	BRAJPN	I	
			Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab	BRAJPNT	I	
			Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE) and Trastuzumab	BRAJPNT	I	
			Palliative Therapy for Metastatic Breast Cancer using Paclitaxel NAB (ABRAXANE)	BRAVABR	I	
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and Paclitaxel NAB (ABRAXANE)	BRAVPPN	I	
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and Paclitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPAC	I	
			Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and Paclitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	BRLACPACG	I	
			Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using Paclitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNAC	I	
			Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: Paclitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	BRLAPNACG	I	
			First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with Paclitaxel NAB (ABRAXANE) and Gemcitabine	GIPGEMABR	I	
			Alternative Treatment of Gynecological Malignancies Using CARBOplatin and Paclitaxel NAB (ABRAXANE)	GOCABR	I	
			Alternative Treatment of Gynecological Malignancies Using Bevacizumab, CARBOplatin and Paclitaxel NAB (ABRAXANE)	GOCABRBEV	I	
			Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, Paclitaxel NAB (ABRAXANE) and Pembrolizumab	GOCXCPNP	I	
Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, Paclitaxel NAB (ABRAXANE), and Pembrolizumab	GOCXCPNP	I				
palbociclib	capsule	Breast	Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor with or without LHRH Agonist	BRAVPALAI	I	
			Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist	BRAVPBFLV	I	
pamidronate	injectable	Breast	adjuvant therapy for breast cancer in post-menopausal women using pamidronate bony metastases associated with breast cancer for patients who do not tolerate oral clodronate	BRAJPAM	I	Not reimbursed for hypercalcemia
			prevention of skeletal related events secondary to breast cancer using pamidronate	BRAVPAM	I	
			Myeloma	multiple myeloma	MYPAM	
panitumumab	injectable	Gastrointestinal	Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer using Panitumumab and Encorafenib	UGIAPANEN	R	
			palliative third-line treatment of metastatic colorectal cancer using panitumumab with wild type KRAS	GIAVPANI	I	
			palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab	GIFFIRPAN	I	
			palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab	GIFFOXPAN	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES		
pazopanib	tablet	Genitourinary	palliative therapy for renal cell carcinoma using pazopanib	GUPAZO	I			
pegaspargase (ONCASPARG®)	injectable	Lymphoma	treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone	LYASPMEDX	I			
			Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	LYGEMOXPEG	I			
			treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide	LYSMILE	I			
			treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma using pegaspargase (ONCOSPARG)	LKNOS, LYNOS	I			
		Pediatric	pediatric patients with leukemia or lymphoma		I			
peginterferon alfa-2a	injectable	Leukemia & BMT	therapy of chronic myeloid neoplasms and hypereosinophilic syndrome	LKPEGIFN	I			
pembrolizumab	injectable	Breast	Adjuvant Treatment of Resected Triple Negative Breast Cancer using Pembrolizumab	BRAJPEM	I			
			Treatment of Metastatic Breast Cancer using Pembrolizumab	BRAVPEM	I			
			Treatment of Metastatic Breast Cancer using 6-Weekly Pembrolizumab	BRAVPEM6	I			
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin	BRAVPGC	I			
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with PAclitaxel	BRAVPP	I			
			Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and PAclitaxel NAB (ABRAXANE)	BRAVPPN	I			
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PAclitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCTAC	I			
			NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PAclitaxel, Followed by DOXOrubicin and Cyclophosphamide	BRPCWTAC	I			
			Gastrointestinal	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using Pembrolizumab	UGIAVPEM	R		
				First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using 6-Weekly Pembrolizumab	UGIAVPEM6	R		
				First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	GIGAVCOXP	I		
				First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	GIGAVFFOXP	I		
				Gynecology	Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Pembrolizumab with or without Bevacizumab	GOXBP	I	
					Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with 6-Weekly Pembrolizumab with or without Bevacizumab	GOXBP6	I	
		Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PAclitaxel and Pembrolizumab	UGOCXCATBP		R			
		Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PAclitaxel, and Pembrolizumab	UGOCXCATP		R			
		Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PAclitaxel NAB (ABRAXANE) and Pembrolizumab	GOXCPCNPB	I				
		Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PAclitaxel NAB (ABRAXANE) and Pembrolizumab	GOXCPCNP	I				
		Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Pembrolizumab	UGOENDAVP	R				
		Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using Pembrolizumab and Lenvatinib	GOENDAVPL	I				
Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using 6-weekly Pembrolizumab and Lenvatinib	GOENDAVPL6	I						



**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
pembrolizumab (cont'd)	injectable	Gynecology Genitourinary	Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using 6-Weekly Pembrolizumab	UGOENDAVP6	R		
			Adjuvant Treatment of Resected Renal Cell Carcinoma using Pembrolizumab	GUAJPEM	I		
			Adjuvant Treatment of Resected Renal Cell Carcinoma using 6-Weekly Pembrolizumab	GUAJPEM6	I		
			treatment of locally advanced or metastatic urothelial carcinoma using pembrolizumab	GUAVPEM	I		
			Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Lenvatinib	GUAVPEML	I		
			Treatment of Metastatic Renal Cell Carcinoma using 6-weekly Pembrolizumab and Lenvatinib	GUAVPEML6	I		
			treatment of locally advanced or metastatic urothelial carcinoma using 6-weekly pembrolizumab	GUAVPEM6	I		
			Treatment of Metastatic Renal Cell Carcinoma Using Pembrolizumab and Axitinib	GUAVPEMAX	I		
			Head and Neck	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Paclitaxel, Carboplatin and Pembrolizumab	HNAVPCPMB	I	
				First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab	HNAVFPMB	I	
				First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Pembrolizumab	HNAVPMBF	I	
				First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using 6-Weekly Pembrolizumab	HNAVPMBF6	I	
		Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Pembrolizumab		HNAVPMBM	I		
		Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using 6-Weekly Pembrolizumab		HNAVPMBM6	I		
		Lung		first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel, carboplatin and pembrolizumab	LUAVPCPMB	I	
				first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab	LUAVPGPMB	I	
				second-line treatment of advanced non-small cell lung cancer using pembrolizumab	LUAVPMB	I	
				treatment of advanced non-small cell lung cancer using 6-weekly pembrolizumab	LUAVPMB6	I	
			first-line treatment of advanced non-small cell lung cancer using pembrolizumab	LUAVPMBF	I		
			first-line treatment of advanced non-small cell lung cancer using 6-weekly pembrolizumab	LUAVPMBF6	I		
			maintenance therapy of advanced non-small cell lung cancer with pembrolizumab	LUAVPMBM	I		
			maintenance therapy of advanced non-small cell lung cancer with 6-weekly pembrolizumab	LUAVPMBM6	I		
			maintenance therapy of advanced non-squamous non-small cell lung cancer with pemetrexed and pembrolizumab	LUAVPPMBM	I		
			first-line treatment of advanced non-squamous non-small cell lung cancer with platinum, pemetrexed and pembrolizumab	LUAVPPMB	I		
		Lymphoma	treatment of relapsed or refractory hodgkin lymphoma using pembrolizumab	LYPEM	I		
			treatment of relapsed or refractory hodgkin lymphoma using 6-weekly pembrolizumab	LYPEM6	I		

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
<b>pembrolizumab (cont'd)</b>	injectable	Skin & Melanoma	Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using Pembrolizumab	SMAJPEM	I	
			Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using 6-Weekly Pembrolizumab	SMAJPEM6	I	
			treatment of unresectable or metastatic melanoma using pembrolizumab	SMAVPEM	I	
			treatment of unresectable or metastatic melanoma using 6-weekly pembrolizumab	SMAVPEM6	I	
<b>emetrexed</b>	injectable	Lung	Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum	LUAJNIVPP	I	
			Adjuvant Cisplatin and Pemetrexed Following Resection of Non-Small Cell Lung Cancer	LUAJPP	I	
			maintenance therapy of advanced non-small cell lung cancer after first-line chemotherapy	LUAVPMTN	I	
			first-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed	LUAVPP	I	
			First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	LUAVPPIPNI	I	
			maintenance therapy of advanced non-squamous non-small cell lung cancer with pemetrexed and pembrolizumab	LUAVPPMBM	I	
			first-line treatment of advanced non-squamous non-small cell lung cancer with platinum, pemetrexed and pembrolizumab	LUAVPPMB	I	
treatment of malignant mesothelioma with platinum and pemetrexed	LUMMPP	I				
<b>pertuzumab</b>	injectable	Breast	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Docetaxel as First-Line Treatment for Advanced Breast Cancer	BRAVPTRAD	I	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Paclitaxel as First-Line Treatment for Advanced Breast Cancer	BRAVPTRAT	I	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer	BRAVTRVIN	I	
<b>plerixafor</b>	injectable		hematopoietic stem cell mobilization	PLERIXAFOR	I	
<b>polatuzumab vedotin</b>	injectable	Lymphoma	Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab	LYPOLABR	I	
<b>pomalidomide</b>	capsule	Myeloma	Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide	UMYISAPOMD	R	
			therapy of multiple myeloma using pomalidomide with dexamethasone	UMYPOMDEX	R	
<b>ponatinib</b>	tablet	Leukemia & BMT	treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia using ponatinib	ULKCMLP	R	
<b>pralatrexate</b>	injectable	Lymphoma	treatment of relapsed or refractory Peripheral T-Cell lymphoma (PTCL) with pralatrexate	LYPRA	I	
<b>prednisolone</b>	suspension	Pediatric	pediatric patients		I	
<b>prednisone</b>	tablet	Genitourinary	palliative therapy for metastatic castration resistant prostate cancer using cabazitaxel and prednisone	GUPCABA	I	
			Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone	GUMCSPABI	I	
			Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and prednisone	UGUPABI	R	
			Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer using Abiraterone and predniSONE	UGUPAJABI	R	
			palliative therapy for metastatic hormone refractory prostate cancer	GUPDOC	I	
			palliative therapy for hormone-refractory prostate cancer using mitoxantrone and prednisone	GUPMX	I	
<b>prednisone</b>	tablet	Lymphoma	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone	LYCHOP	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
<b>prednisone (cont'd)</b>	tablet	Lymphoma	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab	LYCHOPR	I	
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I	
			treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin	LYCHPBV	I	
			treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab	LYCLLCVPR	I	
			advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone	LYCVP	I	
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I	
			treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab	LYCVPR	I	
			therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia or multiple myeloma using cyclophosphamide	LYCYCLO	I	
			Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	LYDARCBD	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
		lymphoma palliative chemotherapy	LYPALL	I		
		Myeloma	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone	MYBLDF	I	
			Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant	MYBLDPRE	I	
			Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant	MYBOPRE	I	
			Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide	MYBORREL	I	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide	MYDARBD	I	
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	MYDARCBD	I	
			treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone	MYDARLD	I	
			Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone	MYDARLDF	I	
			Treatment of Multiple Myeloma using Melphalan and Prednisone	MYMP	I	
treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan	MYMPBOR		I			
		Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. LKNOS)	I		
<b>procarbazine</b>	capsule	Neuro-Oncology	modified PCV chemotherapy of brain tumours using procarbazine, lomustine and vincristine	CNMODPCV	I	
			standard procarbazine for second-line treatment of recurrent brain tumor	CNPROC	I	
		Lymphoma	treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I	
			lymphoma palliative chemotherapy	LYPALL	I	
		Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. CNNOS)	I		
<b>radium-223</b>	radio-pharmaceutical	Genitourinary	therapy for metastatic castration resistant prostate cancer using radium-223	GUPRAD	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
raltitrexed	injectable	Gastrointestinal	adjuvant combination chemotherapy for node-positive colon cancer using oxaliplatin and raltitrexed in patients intolerant to fluorouracil or capecitabine	GIAVRALOX	I	
			Palliative Therapy of Metastatic Colorectal Cancer using Irinotecan and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	GIAVRALIR	I	
			Palliative Therapy of Metastatic Colorectal Cancer using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	GIAVRALOX	I	
			unresectable or metastatic colorectal adenocarcinoma for patients with previous fluorouracil toxicity	GIRALT	I	
ramucirumab	injectable	Gastrointestinal	second-line therapy for metastatic or locally advanced gastric or gastroesophageal junction cancer using weekly paclitaxel and ramucirumab	GIGAVRAMT	I	
regorafenib	tablet	Sarcoma	third line treatment of advanced gastrointestinal stromal cell tumours (GIST's) using regorafenib	SAAVGR	I	
			Treatment of Relapsed or Refractory Advanced Osteosarcoma using Regorafenib	SAAVOR	I	
		Gastrointestinal	treatment of advanced hepatocellular carcinoma using regorafenib	GIREGO	I	
ribociclib	tablet	Breast	Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist	BRAVRBFLV	I	
			Therapy of Advanced Breast Cancer using Ribociclib and Aromatase Inhibitor with or without LHRH Agonist	BRAVRIBAI	I	
ripretinib	tablet	Sarcoma	Fourth-Line Therapy of Advanced Gastrointestinal Stromal Cell Tumours (GIST) Using Ripretinib	SAAVGRIP	I	
rituximab	IV injectable only	Leukemia & BMT	pre-emptive rituximab therapy of Epstein-Barr virus related post-transplant lymphoproliferative disease	BMTLPDRIT	I	
	IV / 1400 mg SC injectable	Lymphoma	treatment of Non-Hodgkin Lymphoma with bendamustine and rituximab	LYBENDR	I	
	IV / 1400 mg SC injectable		treatment of indolent B-cell lymphoma with chlorambucil and rituximab	LYCHLRR	I	
	IV / 1400 mg SC injectable		in combination with CHOP (cyclophosphamide, doxorubicin, prednisone, vincristine), in all stages of newly diagnosed diffuse large B-cell lymphoma and mantle cell lymphoma, advanced stage at diagnosis	LYCHOPR	I	
	IV / 1400 mg SC injectable		central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I	
	IV / 1600 mg SC injectable		treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with bendamustine and rituximab	LYCLLBENDR	I	
	IV / 1600 mg SC injectable		treatment of chronic lymphocytic leukemia with chlorambucil and rituximab	LYCLLCHLR	I	
	IV / 1600 mg SC injectable		treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab	LYCLLCVPR	I	
	IV / 1600 mg SC injectable		treatment of previously untreated chronic lymphocytic leukemia (CLL) with bendamustine and rituximab	LYCLLFBR	I	
	IV / 1600 mg SC injectable		treatment of chronic lymphocytic leukemia or prolymphocytic leukemia with fludarabine and rituximab	LYCLFLUDR	I	

Note: Biosimilar rituximab (RIXIMYO®, RUXIENCE®) is funded for intravenous rituximab started on or after August 1st, 2020. RITUXAN® is funded for intravenous rituximab started prior to and continue beyond August 1st, 2020.

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
<b>rituximab (cont'd)</b>	IV / 1400 mg SC injectable	Lymphoma	treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I	Note: Biosimilar rituximab (RIXIMYO®, RUXIENCE®) is funded for intravenous rituximab started on or after August 1st, 2020. RITUXAN® is funded for intravenous rituximab started prior to and continue beyond August 1st, 2020.
	IV / 1400 mg SC injectable		combination with CVP for advanced stage indolent lymphoma at diagnosis	LYCVPR	I	
	IV / 1400 mg SC injectable		Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and riTUXimab	LYDHAPR	I	
	IV / 1400 mg SC injectable		treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate	LYEPOCHR	I	
	IV / 1600 mg SC injectable		treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab	LYFCR	I	
	IV / 1400 mg SC injectable		treatment of relapsed indolent lymphoma with fludarabine and rituximab	LYFLUDR	I	
	IV / 1400 mg SC injectable		treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab	LYGDPR	I	
	IV / 1400 mg SC injectable		Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide	LYHDMRTEM	I	
	IV / 1600 mg SC injectable		treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab	LYIDELAR	I	
	IV / 1400 mg SC injectable		treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab	LYIVACR	I	
	IV / 1400 mg SC injectable		Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab	LYPOLABR	I	
	IV / 1400 mg SC injectable		treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab	LYRICE	I	
	IV / 1400 mg SC injectable		follicular lymphoma progressive despite alkylating agents and purine analogues (fludarabine or cladribine), post-transplant lymphoproliferative disease, or newly diagnosed (within 6 months) asymptomatic advanced follicular lymphoma	LYRITUX	I	
	IV injectable only		Palliative Therapy For Lymphoma Using Radioimmunotherapy: riTUXimab-Priming for 90Y-Ibritumomab tiuxetan (ZEVALIN®)	LYRITZ	I	
	IV / 1400 mg SC injectable	maintenance treatment of indolent lymphoma	LYRMTN	I		
IV / 1600 mg SC injectable	treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax and rituximab	LYVENETOR	I			
IV injectable only	Pediatric	pediatric patients treated on the COG protocols ANHL0221 for CD20 positive post-transplant lymphoproliferative disease following solid organ transplantation and ANHL01P1 for newly diagnosed advanced B-cell leukemia/lymphoma		I		
<b>romidepsin</b>	injectable	Lymphoma	treatment of relapsed or refractory Peripheral T-Cell lymphoma (PTCL) with romidepsin	ULYROMI	R	
<b>ruxolitinib</b>	tablet	Leukemia & BMT	Treatment of Symptomatic Myelofibrosis with Ruxolitinib Treatment of Polycythemia Vera with Ruxolitinib	LKMFBRUX LKPCVRUX	I I	
<b>sacituzumab govitecan</b>	injectable	Breast	Palliative Therapy for Metastatic Triple Negative Breast Cancer	BRVAVSG	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
<b>sargramostim (SAP)</b>	injectable	Pediatric	pediatric patients with neuroblastoma treated on the COG ANBL0032 protocol pediatric patients with relapsed neuroblastoma treated on the COG ANBL1021 protocol treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in combination with sargramostim, aldesleukin and tretinoin		I	Approval from Health Canada Special Access Programme is required for each patient
<b>selinexor</b>	tablet	Myeloma	Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide	MYBSD	I	
<b>selpercatinib</b>	capsule	Head and Neck	Therapy of Advanced RET Fusion-Positive Differentiated Thyroid Cancer using Selpercatinib  Treatment of Advanced RET-Mutant Medullary Thyroid Cancer using Selpercatinib	HN0TDSSEL HN0TMSEL	I I	
		Lung	Treatment of RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Selpercatinib	LUAVSEL	I	
<b>siltuximab</b>	injectable	Lymphoma	treatment of Multicentric Castleman's Disease (MCD) negative for Human Immunodeficiency Virus (HIV) and Human Herpes Virus-8 (HHV-8) Using siltuximab	LYSILTUX	I	
<b>sorafenib</b>	tablet	Gastrointestinal Genitourinary Leukemia & BMT	Therapy for Advanced Hepatocellular Carcinoma using Sorafenib palliative therapy for renal cell carcinoma in patients after cytokine failure therapy of acute myeloid leukemia using azacitidine and sorafenib	GISORAF GUSORAF LKAMLAS	I I I	
<b>streptozocin</b>	injectable	Gastrointestinal  Not Otherwise Specified	palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin	GIENDO2  Other tumour site code followed by 'NOS' (e.g. GINOS)	I  I	Approval from Health Canada Special Access Programme is required for each patient
<b>sunitinib</b>	capsule	Gastrointestinal Genitourinary Sarcoma	as palliative treatment of advance pancreatic neuroendocrine tumours palliative therapy for renal cell carcinoma in patients who are not suitable candidates for interferon second line treatment of advanced c-kit positive gastrointestinal stromal cell tumours (GIST's) after imatinib	GIPNSUNI GUSUNI SAAVGS	I I I	
<b>tamoxifen</b>	tablet	Breast   Gynecology Head and Neck Sarcoma	Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen neoadjuvant or adjuvant therapy for breast cancer using tamoxifen palliative therapy for breast cancer using a LHRH agonist and tamoxifen palliative therapy for breast cancer endometrial canceron-aromatase inhibitor hormonal treatment of endometrial cancer therapy for advanced ovarian cancer using tamoxifen treatment of recurrent/metastatic salivary gland cancers recurrent desmoid tumors/aggressive fibromatosis	UBRAJABET BRAJLHRHT BRAJTAM BRAVLHRHT BRAVTAM GOENDH GOOVTAM HNSAVTAM SATAM	R I I I I I I I I	
<b>tebentafusp</b>	injectable	Skin & Melanoma	Treatment of Metastatic Uveal Melanoma using Tebentafusp	USMAVTEB	R	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES	
temozolomide	capsule	Neuro-Oncology	concomitant (dual modality) and 12 cycles of adjuvant temozolomide for newly diagnosed astrocytomas and oligodendrogliomas with radiation	CNAJ12TZRT	I		
			concomitant and adjuvant temozolomide for newly diagnosed malignant gliomas with radiation	CNAJTZRT	I		
			treatment of elderly newly diagnosed glioma patient with concurrent and adjuvant temozolomide and radiation therapy	CNELTZRT	I		
			therapy for newly diagnosed malignant brain tumours with MGMT methylation in elderly patients using temozolomide	CNTEM60	I		
			therapy for malignant brain tumours	CNTEMOZ	I		
			therapy for malignant brain tumours using metronomic dosing of temozolomide	CNTEMOZMD	I		
		Gastrointestinal	therapy for recurrent malignant brain tumours using temozolomide and etoposide	CNTMZETO	I		
			palliative therapy of metastatic neuroendocrine cancer using temozolomide and capecitabine	GIAVTZCAP	I		
			Lymphoma	Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide	LYHDMRTEM	I	
				pediatric patients with brain tumours		I	
				pediatric patients treated on the COG protocol ANBL0421 for recurrent neuroblastoma		I	
			Sarcoma	pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol		I	
therapy for advanced solitary fibrous tumours and hemangiopericytoma using temozolomide and bevacizumab	SATEMBEV	I					
Skin & Melanoma	palliative therapy for malignant melanoma with brain metastases	SMAVTMZ	I				
temsirolimus	injectable	Genitourinary	therapy for advanced renal cancer using temsirolimus	GUTEM	I		
		Pediatric	treatment of recurrent/refractory rhabdomyosarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol		I		
teniposide	injectable	Not Otherwise Specified		Tumour site code followed by 'NOS' (e.g. GUNOS)	I		
testosterone enanthate	injectable	Breast	palliative therapy for metastatic breast cancer	BRAVTEST	I	Not reimbursed for symptom management or appetite stimulation	
thioguanine	tablet	Not Otherwise Specified		Tumour site code followed by 'NOS' (e.g. LYNOS)	I		
thiotepa	injectable	Miscellaneous Origins	therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine	MOIT	I		
		Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. GUNOS)	I		
thyrotropin alfa	injectable	Head and Neck	radioiodine imaging in patients with thyroid cancer and treatment	HNOTTSH	I		
tisagenlecleucel (KYMRIA <sup>®</sup> )	CAR T-cell	Pediatric	Treatment of pediatric and young adult patients up to and including 25 years of age with B-cell acute lymphocytic leukemia (ALL) refractory to or relapsed after allogeneic stem cell transplantation (SCT) or otherwise ineligible for SCT, or experienced second or later relapse.	PECARTALL	R		
		Lymphoma	Third line treatment of adults with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)	LYCARTDL3	R		
topotecan	injectable	Gynecology	treatment of relapsed/progressive epithelial ovarian, fallopian tube or primary peritoneal cancer using topotecan	GOOVTOP	I		
		Lung	second line treatment of recurrent small cell lung cancer	LUSCTOP	I		
			pediatric sarcoma		I		
		Pediatric	intermediate-risk (COG ANBL0532) and high risk (COG ANBL0531) pediatric neuroblastoma		I		
Sarcoma	summary for treatment of recurrent/refractory neuroblastoma, ewing's sarcoma, osteogenic sarcoma or rhabdomyosarcoma with topotecan/cyclophosphamide	SAAVTC	I				

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
trametinib	tablet	Skin & Melanoma	adjuvant treatment of stage III and IV, BRAF-mutated, fully resected melanoma using dabrafenib and trametinib	SMAJDT	I	
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib and trametinib	SMAVDT	I	
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using trametinib	SMAVTRA	I	
trastuzumab	injectable	Breast	neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTT	I	<p>Note: Biosimilar trastuzumab (HERZUMA®, TRAZIMERA®, ONTRUZANT®) is funded for treatment started on or after February 1st, 2020.</p> <p>HERCEPTIN® is only funded for:</p> <ul style="list-style-type: none"> <li>• treatment started prior to February 1st, 2020, or</li> <li>• treatment started prior to September 1, 2022 when used with pertuzumab for advanced breast cancer (BRAVPTRAD, BRAVPTRAT)</li> </ul>
			neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab	BRAJACTTG	I	
			neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and trastuzumab	BRAJDCARBT	I	
			neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRAJFECDT	I	
			Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE) and Trastuzumab	BRAJPNT	I	
			Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab	BRAJPNCT	I	
			neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel and cyclophosphamide	BRAJTDC	I	
			Adjuvant Therapy for Breast Cancer using Trastuzumab Following the Completion of Chemotherapy (Sequential)	BRAJTR	I	
			adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab	BRAJTTW	I	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Docetaxel as First-Line Treatment for Advanced Breast Cancer	BRAVPTRAD	I	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Paclitaxel as First-Line Treatment for Advanced Breast Cancer	BRAVPTRAT	I	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer	BRAVPTRVIN	I	
			palliative therapy for metastatic breast cancer using trastuzumab and capecitabine	BRAVTCAP	I	
			single agent therapy for metastatic breast cancer progressing after 1 prior regimens (e.g., taxane) and responding to trastuzumab in combination with paclitaxel, with paclitaxel and carboplatin, or with vinorelbine	BRAVTR	I	
			Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and Capecitabine	UBRAVTTCAP	R	
treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab	BRLAACDT	I				
Gastrointestinal			Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab	GIGAVCCT	I	
			palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab	GIGAVCFT	I	
			palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab	GIGAVCOXT	I	



**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
trastuzumab (cont'd)	Injectable	Gastrointestinal	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin	GIGAVFFOXT	I	Note: Biosimilar trastuzumab (HERZUMA®, TRAZIMERA®, ONTRUZANT®) is funded for treatment started on or after February 1st, 2020. (See above)
			continuation of palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using trastuzumab	GIGAVTR	I	
trastuzumab emtansine (KADCYLA)	injectable	Breast	adjuvant therapy for breast cancer using trastuzumab emtansine (KADCYLA)	UBRAJKAD	R	
			palliative therapy for metastatic breast cancer using trastuzumab emtansine (KADCYLA)	BRAVKAD	I	
trastuzumab deruxtecan (ENHERTU)	injectable	Breast	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)	BRAVENH	I	
treosulfan	injectable	Leukemia & BMT	pre-conditioning therapy with treosulfan for pediatric patients at risk for busulfan-related toxicity prior to hematopoietic stem cell transplantation for malignant conditions	BMTNOS	I	
		Pediatric			R	
tretinoin (VESANOID®)	capsule	Leukemia & BMT	acute promyelocytic leukemia	LKNOS	I	
			first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide and tretinoin	LKATOATRA	I	
			first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin	LKATOP	I	
			induction and consolidation therapy of relapsed acute promyelocytic leukemia using arsenic trioxide and tretinoin (All-Trans Retinoic Acid)	LKATOR	I	
		Pediatric	Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and Dexamethasone on the COG AAML1331 Study		I	
			treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in combination with sargramostim, aldesleukin and tretinoin		I	
trifluridine-tipiracil	tablet	Gastrointestinal	Third- or Later-Line Therapy for Advanced Gastroesophageal Carcinoma using Trifluridine-Tipiracil	GIGAVTRFT	I	
tucatinib	tablet	Breast	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and Capecitabine	UBRAVTTCAP	R	
vandetanib	tablet	Head and Neck	treatment for locally advanced or metastatic medullary thyroid cancer using vandetanib	HNOTVAN	I	
vemurafenib	tablet	Skin & Melanoma	treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib	SMAVVM	I	
			treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib and cobimetinib	SMAVVC	I	
venetoclax	tablet	Leukemia & BMT	Therapy of Acute Myeloid Leukemia using Azacitidine and Venetoclax	ULKAMLAVEN	R	
		Lymphoma	treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax	ULYVENETO	R	
			treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax and rituximab	LYVENETOR	I	
			Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Obinutuzumab	LYVENOB	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
vinblastine	injectable	Genitourinary	therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin	GUMVAC	I	
			consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna	GUVEIP	I	
		Kaposi's Sarcoma	therapy for Kaposi's Sarcoma using vinblastine-vincristine	KSVB	I	
			Lymphoma	treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine	LYABVD	I
		Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin		LYAVDBV	I	
		Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients 60 Years or Older		LYBVAVDBV	I	
		treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone		LYCVPABO	I	
		lymphoma palliative chemotherapy		LYPALL	I	
		Sarcoma	palliative therapy for aggressive fibromatosis using weekly or alternate week methotrexate and vinblastine intravenously	SAMV	I	
Not Otherwise Specified		Other tumour site code followed by 'NOS' (e.g. LYNOS)	I			
vincristine	injectable	Neuro-Oncology	adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour	CNCCV	I	
			modified PCV chemotherapy of brain tumours using procarbazine, lomustine and vincristine	CNMODPCV	I	
		Genitourinary	Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin	GUBDDMVAC	I	
			Gynecology	therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folic acid), dactinomycin, cyclophosphamide and vincristine	GOTDEMACO	I
		Kaposi's sarcoma		therapy for Kaposi's Sarcoma using vinblastine-vincristine	KSVB	I
		Lung	treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine	LUOTCAV	I	
			treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine	LUSCCA	I	
		Lymphoma	treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone	LYCHOP	I	
			treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab	LYCHOPR	I	
			central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma	LYCHOPRMTX	I	
			treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab	LYCLLCVPR	I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
vincristine (cont'd)	injectable	Lymphoma	treatment of Burkitt's Lymphoma and Leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab	LYCODOXMR	I	
			advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone	LYCVP	I	
			treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone	LYCVPPABO	I	
			treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab	LYCVPR	I	
			treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate lymphoma palliative chemotherapy	LYEPOCHR	I	
		Sarcoma	SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>TWO</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT2W	I	
			SAIME alternating with SAVAC or SAVACM with filgrastim support at <u>THREE</u> weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	SAALT3W	I	
			treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide	SAVAC	I	
			Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna	SAVACM	I	
			Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide	SAVDC	I	
Not Otherwise Specified	Other tumour site code followed by 'NOS' (e.g. LYNOS)		I			
vinorelbine	injectable	Breast	palliative therapy for metastatic breast cancer	BRAVNAV	I	
			Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer	BRAVPTRVIN	I	
		Gynecology	Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine	GOOVBEVV	I	
			palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer	GOOVVIN	I	
		Head and Neck	combination with cisplatin as treatment of advanced salivary gland cancers with cisplatin and vinorelbine	HNSAVNP	I	
			adjuvant cisplatin and vinorelbine following resection of stage I, II and IIIA non-small cell lung cancer	LUAJNP	I	
		Lung	combination with cisplatin as treatment for advanced non-small cell lung cancer	LUAVNP	I	
			advanced non-small cell lung cancer in elderly patients	LUAVVIN	I	
			malignant mesothelioma	LUMMVIN	I	
		Lymphoma	Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and Doxorubicin Pegylated Liposomal	LYGVLD	I	
			pediatric patients treated on the COG protocol AHOD0521 for refractory/recurrent Hodgkin's disease		I	
		Pediatric	treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)		I	
			treatment of recurrent/refractory rhabdomyosarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol		I	

**BC Cancer Benefit Drug List  
April 2024**

DRUG	DOSAGE FORM	TUMOUR SITE	APPROVED INDICATIONS	PROTOCOL CODES	CLASS	NOTES
vismodegib	capsule	Skin & Melanoma	treatment of metastatic or locally advanced basal cell carcinoma	SMAVVIS	I	
yttrium-90	injectable	Gastrointestinal	Transarterial Radioembolisation (TARE) for Locally Advanced Cholangiocarcinoma or Gallbladder Carcinoma Not Amenable for Surgical Resection	GIBYTT	I	
			Transarterial Radioembolisation (TARE) for Hepatocellular Cancer or Neuroendocrine Tumours with Hepatic Disease	GIYTT	I	
zanubrutinib	capsule	Lymphoma	Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Zanubrutinib	LYCLLZANU	I	
			Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (LPL) using Zanubrutinib	ULYWZANU (previously ULYZANU)	R	
zoledronic acid	injectable	Breast	adjuvant therapy for breast cancer in post-menopausal women using zoledronic acid	BRAJZOL5	I	
			adjuvant therapy for breast cancer in post-menopausal women using 3-monthly zoledronic acid	BRAJZOL2	I	
			treatment of acute bone pain secondary to breast cancer metastases using IV zoledronic acid	BRAVZOL	I	
		Myeloma	treatment of multiple myeloma with zoledronic acid	MYZOL	I	
<b>Protocol Code Definitions</b>						
Bone Marrow Transplantation		BMT				
Breast		BR				
Gastrointestinal		GI				
Genitourinary		GU				
Gynecologic		GO				
Head and Neck		HN				
Kaposi's sarcoma		KS				
Leukemia		LK				
Lung		LU				
Lymphoma		LY				
Miscellaneous Origin		MO				
Myeloma		MY				
Neuro-Oncology		CN				
Ocular		OC				
Primary Unknown		PU				
Sarcoma		SA				
Skin & Melanoma		SM				
Tumour Agnostic		TA				